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 Proteins are one of the most intriguing, versatile, and complex macromolecules in living systems.  
Proteins rarely function independently and perform their activities through a multitude of interactions 
with other proteins or molecules.  Such molecular interactions are fundamental to almost all biological 
processes and their disruption is often associated with cellular irregularities and disease states.  It is 
therefore of immense importance and interest to identify and characterize the binding interfaces of these 
biologically relevant molecular interactions.   
 
 NMR spectroscopy is unparalleled in its ability to monitor molecular interactions in solution at 
atomic level over a wide range of affinities.  In this body of work, various NMR methods were 
successfully used to study and characterize the protein-ligand interactions of three discrete systems: the 
bacterial type III secretion system (T3SS), the post-translational SUMO modification system, and post-
transcriptional regulation by the RNA binding protein HuR.  
 
 The T3SS is a macromolecular structure assembled by many Gram-negative bacterial pathogens, 
such as, Shigella flexneri, Yersinia pestis, and multi-drug resistant Pseudomonas aeruginosa, to cause 
infectious diseases.  The structural component of the T3SS, the needle apparatus, consists of a base, a 
needle, a tip complex, and a translocon.  Because the needle apparatus is exposed on the bacterial surface, 
present only among the pathogens, and essential for the virulence, disrupting the needle assembly is an 
attractive strategy for the development of novel anti-virulence drugs.  However, this approach demands a 
detailed understanding of the protein-protein interactions involved in the needle assembly.  Here, NMR 
methods were used to characterize the protein-protein interactions that are important in the assembly of 
the tip-translocon complex in the Shigella T3SS.  Additionally, fragment-based screening was performed 
to identify small molecule binders of the tip proteins from Yersinia and Pseudomonas T3SS.  The hits 
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were subsequently validated and characterized using NMR spectroscopy.  Our results provide novel 
insight into the assembly of the needle apparatus and reveal the first small molecules that directly bind to 
the tip proteins of Yersinia and Pseudomonas T3SS. 
 
 Small ubiquitin-like modifier (SUMO) conjugation is a reversible post-translational modification 
process that can modulate biochemical and cell biological functions of the target protein substrate.  
SUMO E3 ligases are the enzymes that carry out the final step in SUMO conjugation pathway and 
facilitate the transfer of SUMO to the target protein.  Prior to this work, SUMO binding by the PIAS 
family of E3 ligases was poorly understood.  Here, using NMR spectroscopy, the protein-protein 
interactions involved in the SUMO-PIASy binding were characterized.  The NMR binding studies 
surprisingly uncovered a novel SUMO-interacting motif in the E3 ligase PIASy, which was found to be 
essential for the ligase activity of PIASy.     
 
 The RNA binding protein HuR binds to adenine- and uridine-rich elements (AREs) located in the 
untranslated region of target mRNAs, regulating their stability and translation.  HuR-ARE interaction 
contributes to carcinogenesis by stabilization of oncogenic mRNAs.  HuR is overexpressed in a broad 
range of human cancers and associated with poor clinical outcome.  In vitro and in vivo studies have 
demonstrated that HuR is an attractive therapeutic target.  Drugs that disrupt HuR-ARE interaction could 
potentially inhibit cancer growth and persistence.  Here, a fungal natural product azaphilone (AZA-9) was 
identified as a novel disruptor of HuR-ARE interaction using fluorescence polarization based screening.  
AZA-9 binding to HuR was validated and characterized by NMR methods.  Results of NMR studies 
suggest that AZA-9 binds in the ARE-binding cleft of HuR, and thus competitively inhibits the HuR-ARE 
interaction.  
 
 The work presented in this dissertation illustrates the strength of NMR spectroscopy and its wide 
applicability as a tool to characterize and understand diverse interactions of proteins. 
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1.1.  NMR studies of protein interactions 
 
 Structural and functional characterization of molecular interactions is fundamental to the 
understanding of many essential biological processes (1-3).  Often times, such interactions are weak and 
transient, and therefore, difficult to investigate by biophysical methods such as pull-down, and 
crystallography.  Nuclear Magnetic Resonance (NMR) spectroscopy is an exquisitely powerful tool for 
analyzing these weak biomolecular interactions in atomic details at physiological conditions (1-6).  
 
1.1.1.  NMR chemical shift mapping 
 
 One of the most widely used NMR methods for studying molecular interactions is called NMR 
chemical shift mapping (or differential chemical shift perturbation method) (7,8).  It is a robust, reliable, 
and relatively straightforward technique that can provide information about both location and strength of 
the binding event from the same set of measurements (7-9).  In protein interaction studies, NMR chemical 
shift mapping monitors changes in the chemical shifts of an isotopically labeled protein induced upon the 
addition of an unlabeled ligand/binding partner (e.g. a protein, nucleic acid, or a small molecule).  NMR 
chemical shifts are extremely sensitive to the chemical environment of the nucleus, and therefore, NMR-
active nuclei located at the binding interface typically experience largest changes in the chemical shifts 
upon complex formation, thus enabling determination of molecular interaction interfaces (6-9).  
 
 3 
1.1.2.  NMR exchange regimes in protein-ligand interactions   
 
 The appearance of the NMR spectra in protein interaction studies varies depending on binding 
affinity of the ligand (10).  Three broad NMR chemical exchange conditions, namely, slow, intermediate, 
or fast, can be observed (Figure 1-1).  Slow exchange on NMR chemical shift time scale indicates a slow 
dissociation complex (tight-binding interactions) that rarely dissociates during the detection period of the 
NMR experiment (5,8,10).  Two sets of resonances/peaks corresponding to the free and ligand-bound 
protein are observed.  As the concentration of the ligand is increased, new peaks from the bound state 
grow in intensity while simultaneously peaks from the free protein gradually decrease in intensity until 
they disappear (Figure 1-1a).  Significant interconversion between the free and the ligand-bound state 
result in the intermediate exchange on NMR time scale.  The signals become weaker and poorly defined 
(5,8,10).  Peaks affected by the interaction show substantial reduction in the intensity and may even 
disappear during the titration.  The peak broadening may also be accompanied by shifts in the peak 
positions (Figure 1-1b).  Lastly, fast dissociation complexes (or weak binding interactions) result in fast 
exchange on NMR time scale.  The extremely fast interconversion between the free and ligand-bound 
forms during the detection period of the NMR experiment results in the observed chemical shift to be the 
weighted average of the chemical shifts for the free and bound form (5,8,10).  The peaks move 
continuously from free to the bound position with increasing ligand concentrations (Figure 1-1c).  The 
three NMR chemical exchange regimes, slow, intermediate, and fast are typically associated with 
submicromolar, micromolar and high micromolar to millimolar dissociation constants, respectively 
(5,6,8,10).  Irrespective of the kind of NMR chemical exchange regime, the bound state of the complex 





Figure 1-1.  Exchange regimes on the NMR chemical shift time scale for protein-ligand complex 
formation.  Distinct signals can be observed for the free and ligand-bound state of protein, at P and PL, 
respectively.  The exchange regime (a) slow, (b) intermediate, or (c) fast, is strongly influenced by the 
ligand binding affinity.  Figure adapted from (10).  
 
1.1.3.  Isotopic labeling for protein interaction studies  
 
 Characterization of the protein interactions using NMR spectroscopy requires labeling the protein 
of interest with stable NMR isotopes.  Although the predominant hydrogen isotope 1H isotope is NMR 
active, the most abundant nitrogen (14N) and carbon (12C) isotopes are NMR inactive and need to be 
substituted with NMR active nuclei (15N and 13C) through isotopic enrichment.  Labeling with stable 
isotopes is routinely achieved by expressing the protein of interest in bacteria grown on appropriate 
minimal media with desired isotopically labeled nitrogen or/and carbon sources (4-6).   
 
 Based on the type of the experiment to be collected, protein size and quality of the NMR data, 
different labeling schemes can be utilized in the NMR studies of protein interactions.  The labeling 
schemes can be broadly classified into two categories: uniform and selective labeling.  Uniform labeling 
produces a protein with uniformly incorporated NMR active isotope(s) at all the sites, whereas with 
selective labeling, the protein is enriched with an isotope only at specific sites of interest.  Selective 
labeling is generally used with large proteins (MW ~25 kDa or more) in order to reduce the spectral 
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overlap and complexity of the NMR datasets for unambiguous analysis (5,9).  Different isotopic labeling 
strategies include: 
 
 Uniform 15N labeling.  This is the simplest and the cheapest form of isotopic labeling achieved 
by growing bacteria in media supplemented with 15N-ammonium chloride as the nitrogen source.  15N-
labeled proteins can be used to acquire standard backbone amide correlation experiments such as 2D 1H-
15N HSQC (or TROSY) to examine whether the protein is folded and to test the effect of different 
experimental conditions such as, temperature, pH, and buffers on spectral quality of the protein for 
optimization (1,5,11).  Based on the data quality, uniform 15N-labeled proteins can be used as a probe to 
investigate ligand interactions.  
 
 Uniform 15N, 13C and 2H labeling.  Along with 15N-ammonium chloride as the nitrogen source, 
the bacterial growth media can be supplemented with 13C-glucose as the carbon source to produce 15N and 
13C double-labeled proteins.  These are generally used for acquisition of 3D NMR experiments to perform 
resonance assignments, which is crucial information for identification of the residues involved in the 
interactions.  For large proteins, instead of H2O, the proteins are expressed in D2O-based minimal media 
(2H labeling) to improve the relaxation properties of protein and thereby, improving the overall NMR 
spectral quality.  Additionally, when partial deuteration is not sufficient (especially for very large proteins, 
> 30-35 kDa), 13C-glucose is often replaced with deuterated d7-13C-glucose to further enhance the 
deuteration levels in protein, and thus, gaining on NMR quality (4,5,8,9,11). 
 
 15N amino acid specific labeling.  NMR interaction studies of large proteins is often complicated 
by significant spectral overlap or poor resolution.  In such cases, it is beneficial to label the backbone 
amides of few specific amino acids in the protein to decrease crowding in the spectra and monitor amino 
acids of interest without interference from other signals.  Besides serving as a probe for protein 
interaction studies, 15N amino acid specific labeling is also useful in the NMR assignment process.  15N 
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amino acid specific labeling is achieved by supplying media with a specific 15N-labeled amino acid of 
interest, while all the remaining amino acids are provided in the unlabeled form.  However, due to 
metabolic conversion between amino acids in the biosynthetic pathway of the cell, the method can mis-
incorporate 15N label in undesired amino acids, also known as isotope scrambling.  For amino acids, Ala, 
Ile, Leu, Val, Lys, Met, Phe, and Tyr, scrambling is minimal and specific labeling is routinely performed, 
but amino acids that are higher up or intermediates in the metabolic pathway, such as, Asp, Asn, Glu, and 
Gln, specific labeling can be particularly challenging due to severe interconversion (5,9,10).  
 
 Side chain methyl ILV (Ile, Leu, and Val) labeling.  This method involves use of synthetic 13C-
keto acids as precursors to selectively label the side chain methyl groups of isoleucine (13C1), leucine 
(13C), and valine (13C) residues in the protein of interest.  An extension (or variant) of the ILV labeling 
involving side chain methyl group labeling of alanine (13C), methionine, and/or threonine residues is 
also available.  The 1H-13C NMR signals from side chain methyl groups of protein with inherently high 
sensitivity, sharp NMR resonances and favorable relaxation properties offer a powerful approach for the 
spectroscopic studies of large proteins.  Since most protein interactions involve hydrophobic interfaces 
and methyl groups frequently occur at the hydrophobic cores of protein, sensitive 13C methyl groups 
provide remarkable probes to qualitatively characterize protein-ligand interactions (5,9,12,13).  Side chain 
methyl labeling can also be carried out in combination with the previously described 15N backbone 
labeling to simultaneously investigate the effect of ligand binding on side chain and backbone groups 
using the same NMR sample. 
 7 
1.1.4.  Other NMR methods for characterizing protein-ligand interactions 
 
Paramagnetic relaxation enhancement (PRE).  In addition to NMR chemical shift mapping, a sensitive 
NMR method based on PRE can be employed to study weak protein-protein interactions.  PRE studies 
require paramagnetic spin labels that are attached to one of the two interacting proteins through a surface-
exposed cysteine residue.  The PRE effect can be detected over a long range (up to 20-25 Å) using 
nitroxide spin labels, such as, MTSL.  The spin-labeled protein is titrated with an isotopically labeled 
binding partner and residues at the interaction interface due to the close proximity to the paramagnetic 
label experience ‘enhanced relaxation’ and display significant reduction in the peak intensities, thus 
facilitating determination of the interaction surfaces (5,9,14,15).  
 
Saturation transfer difference (STD) spectroscopy.  In contrast to the previously described protein-
detected NMR methods, STD NMR is a ligand-observed 1D-NMR technique used in the characterization 
of weak protein-ligand interactions.  The method is based on the nuclear Overhauser effect (NOE) and 
involves observing the effect of selective saturation of the protein signals on the ligand signals (4,6,16).  
STD-NMR experiment is frequently used as a screening tool in the drug discovery process and is useful 
for identifying ligand moieties responsible for binding (16,17).  
 
 In this dissertation, I took advantage of various NMR methods, such as, chemical shift mapping, 
PRE, and STD, and different isotope labeling strategies, such as, 15N, 13C ILV, 15N amino acid specific, 
and deuteration, to characterize molecular interactions involved in three distinct systems: the bacterial 




1.2.  The type III secretion system (T3SS) 
 
 Many pathogenic Gram-negative bacteria assemble a protein nanoinjector called the type III 
secretion system (T3SS) to inject virulence effector proteins directly into the eukaryotic host cells to 
initiate infection (18-20).  Bacteria harboring the T3SS include the causative agents of bacillary dysentery 
(Shigella flexneri), typhoid fever (Salmonella typhimurium), bubonic plague (Yersinia pestis), secondary 
hospital infections (Pseudomonas aeruginosa), and sexually transmitted diseases (Chlamydia 
trachomatis) (21).  Together, they are responsible for millions of deaths worldwide each year.  In the 
United States alone, these pathogens result in an estimated 2 million infections and 23,000 deaths per year 
(22).  The rise of antibiotic resistance among these pathogens poses a major global health concern (22).  
Since the T3SS is indispensable in the pathogenesis of these clinically relevant Gram-negative pathogens, 
disrupting the assembly of the T3SS represents an attractive target for the development of novel anti-
infectives (23-25). 
 
1.2.1.  Components of the T3SS 
 
 The T3SS consists of a needle apparatus, effector proteins, and chaperones (Figure 1-2).  The 
structural component of the T3SS, the needle apparatus, works together with an export apparatus and an 
ATPase complex to secrete the effector proteins directly into eukaryotic host cells.  Chaperones serve as 
regulators of secretion by forming complexes with effectors and other T3SS structural proteins while 
inside the bacterial cytoplasm to maintain them in a pre-active state (20,26).  The needle apparatus is 
assembled from over 20 different proteins and is composed of a base that spans the bacterial membranes, 
an external needle with a 25 Å wide channel, a tip complex, and a translocon (Figure 1-2B) (20,27,28).  
The tip complex plugs the needle until contact with host cell is established (29).  Upon host cell contact, a 
translocon is assembled between the needle tip complex and the host cell.  The translocon creates a pore 
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in the host cell membrane to allow the passage of effector proteins into the host cell cytoplasm.  Once 
inside the host cytoplasm, effectors modulate various host cell pathways, such as, cytoskeletal dynamics, 
and cell signaling, to enable the pathogen to invade, survive and multiply within the host environment 
(28,30).  High-resolution atomic models of the base and the needle are currently available (30-33).  





Figure 1-2.  The bacterial type III secretion system.  (A) Electron micrograph of purified Salmonella 
T3SS needle complexes (34).  (B) Cartoon of the T3SS.  The needle apparatus consists of a base, an 
extracellular needle, a tip complex, and a translocon.  Gram-negative pathogens utilize the needle 
apparatus to deliver effector proteins directly into the host cytoplasm to initiate infectious diseases.  The 
figure is adapted from (27). 
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1.2.2.  The tip complex and the translocon 
 
 On top of the needle sits a tip complex formed by an estimated four to six copies of the tip protein 
(Table 1-1), IpaD (in Shigella), SipD (in Salmonella), BipD (in Burkholderia), LcrV (in Yersinia), or 
PcrV (in Pseudomonas) (20,26,28).  The multi-functional tip proteins play crucial roles in host cell 
sensing, translocon assembly, and effector secretion regulation (28,35).  The atomic structures of tip 
proteins are known (36-39).  IpaD, SipD, and BipD (belonging to the Shigella family) show an overall 
oblong shape and contain an N-terminal -helical hairpin, a long central coiled-coil, and a distal region 
with mixed - structural elements (37,38).  Dumbbell-shaped LcrV (from the Yersinia family) although 
contains the conserved central coiled-coil domain and a less-structured distal α-β domain, it lacks the N-
terminal -helical hairpin and instead, possess a globular N-terminal domain (36,39).  Specific functions 
have been proposed for these distinct domains.  The highly conserved central coiled-coil region of the tip 
proteins has been shown to be important for interaction with the needle proteins (15,40).  The N-terminal 
-helical hairpin found in the Shigella family functions as a self-chaperone to prevent premature 
oligomerization of the tip proteins within the bacterial cytoplasm (37).  In the Yersinia family that lacks 
the self-chaperoning domain, small cytoplasmic proteins, LcrG and PcrG, have been shown to function as 
cognate chaperones for the tip proteins LcrV and PcrV, respectively (41).  Other than the chaperone role, 
LcrG and PcrG also facilitate secretion of their respective tip proteins and play important roles in effector 
secretion regulation in the Yersinia and Pseudomanas T3SS (26,28).  
 
The tip complex serves as a platform for the formation of the translocon.  The translocon is 
assembled from two integral membrane proteins, the major and the minor translocon protein, termed 
based on the difference in their molecular weights (Table 1-1) (28).  IpaB and IpaC (in Shigella), SipB 
and SipC (in Salmonella), YopB and YopD (in Yersinia), and PopB and PopD (in Pseudomonas) are the 
major and the minor translocon proteins, respectively (26,28).  The translocon proteins are responsible for 
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the formation of the translocation pore in the target host cell membrane to deliver effector proteins into 
the host cell cytoplasm.  The atomic structure of any full-length translocon protein is currently unknown, 
however partial crystal structures of a protease resistant soluble N-terminal ectodomain from major 
translocon proteins IpaB and SipB displayed the presence of -helical anti-parallel coiled-coil motifs (42).  
The assembly mechanism and membrane insertion of the translocon proteins is not understood. 
 
Bacteria Disease Base Needle Tip Translocon 
Shigella Shigellosis MxiD, MxiI, 
MxiJ, MxiG 
MxiH IpaD IpaB, IpaC 
Salmonella  Salmonellosis InvG, PrgJ, 
PrgK, PrgH 
PrgI SipD SipB, SipC 
Yersinia Bubonic Plague YscC, YscI, 
YscJ, YscD 
YscF LcrV YopB, YopD 
Pseudomonas Infection in 
immunocompromised 
PscC, PscI,  
PscJ, PscD 
PscF PcrV PopB, PopD 
 
Table 1-1.  List of homologous proteins of the T3SS needle apparatus from various bacteria. 
 
Although in the absence of the tip protein, the translocon proteins can be efficiently secreted, they 
cannot insert into the host cell membrane (26), indicating the importance of the tip-translocon protein-
protein interactions for the assembly of a functional translocon.  The way in which the tip protein interacts 
with the translocon protein is poorly characterized.  In this dissertation, I used NMR chemical shift 
mapping and PRE methods to characterize the interaction between the Shigella tip protein IpaD and the 
translocon protein IpaB.  The results of IpaD-IpaB protein-protein interaction studies are described in 
Chapter 2. 
 
The rise of antibiotic resistance in pathogens requires new targets for developing novel anti-
bacterials (22).  Because of the essential role of T3SS in bacterial virulence, it is an attractive target for 
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the development of novel anti-infectives (23-25).  An initial step in the development of T3SS-based anti-
infectives is the identification of small molecules that can bind to T3SS proteins.  In this direction, SPR 
screening was performed to identify small molecule binders of the virulent tip proteins LcrV and PcrV.  
The identified hits were validated and characterized using ligand and protein-detected NMR methods.  
The results of these protein-small molecule interaction studies and the first methyl ILV assignments from 
the Yersinia family of tip proteins are presented in Chapter 3.  
 
The key internal findings and recommendations for future T3SS molecular interaction studies are 
summarized in Chapter 4. 
 
 
1.3.  The small ubiquitin-like modifier (SUMO) conjugation  
 
 SUMOylation (or small ubiquitin-like modifier conjugation) is a reversible post-translational 
modification process that regulates diverse cellular processes, such as, transcription, replication, DNA 
repair, chromosome segregation, and signal transduction, and is essential for the survival of most 
organisms (43,44).  The three-dimensional structure of SUMO proteins closely resembles that of ubiquitin.  
However, they share less than 20% sequence identity and have different overall surface electrostatics 
(45,46).  SUMO is expressed by all eukaryotes, but is absent from bacteria and archaea.  Organisms like 
yeast, C. elegans, and D. melanogaster, have a single SUMO gene, whereas plants and vertebrates 
express several SUMO proteins (44,45).  Humans express at least four SUMO isoforms, SUMO-1 
through SUMO-4, each encoded by a different gene.  SUMO-1, 2, and 3 are ubiquitously expressed and 
participate in SUMOylation, however, it remains unclear whether SUMO-4, which is mainly expressed in 
kidney and spleen, can be processed or conjugated to cellular proteins (43-45).  SUMO-2 and SUMO-3 
share ~97% sequence identity and are often referred to as SUMO-2/3.  In contrast, SUMO-1 shares less 
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than 50% sequence identity to SUMO-2/3 (43-47).  SUMO-1 and SUMO-2/3 are functionally distinct.  
While SUMO-2/3 can engage in SUMO-chain formation owing to the presence of SUMO-consensus 
motifs (ψKXE) in their N-terminal extensions, SUMO-1 lacks the SUMO-consensus site and is unable to 
form SUMO chains.  Furthermore, SUMO-1 and SUMO-2/3 respond differently to stress conditions and 
display preferential substrate binding (43,44,46). 
 
1.3.1.  The SUMOylation pathway 
 
 Similar to the ubiquitination pathway, SUMO proteins are covalently conjugated to the target 
substrate by an enzymatic cascade involving E1, E2, and E3 enzymes (Figure 1-3A) (43,45).  The 
process initiates with the proteolytic processing of the newly synthesized SUMO by SENPs (SUMO 
specific proteases) to reveal the C-terminal Gly-Gly (GG) motif in the ‘mature’ SUMO.  The mature 
SUMO undergoes an ATP-dependent activation by SUMO E1 activating enzyme, Aos1/Uba2.  Following 
activation, SUMO is transferred to the catalytic cysteine residue of the SUMO E2 conjugating enzyme, 
Ubc9, forming an E2~SUMO thioester complex.  Ubc9 can then catalyze conjugation to the target 
substrate in an E3 ligase independent manner via recognition of the SUMO consensus motif (ψKXE, 
where ψ is a large hydrophobic residue, K is the acceptor lysine residue, X represents any residue, and E 
is an acidic residue) and form an isopeptide bond between the C-terminal glycine residue of SUMO and 
the acceptor lysine residue in the substrate.  However, this step is usually facilitated by SUMO E3 ligases 
and is particularly important when SUMO conjugation has to occur at non-consensus lysine residues in 
the substrate.  SUMO modification provides a platform for new protein-protein interactions.  SUMO-
modified substrates can interact with SUMO-binding proteins through their SUMO-interacting motifs 
(SIMs).  SUMOylation is a reversible process, SENP proteases can de-conjugate SUMO from the 
substrate and free SUMO may be utilized for another round of modification (Figure 1-3A) (43-46). 
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1.3.2.  The SUMO E3 ligase, PIASy 
 
 All SUMO modifications use the same E1 (Aos1/Uba2) and E2 (Ubc9) enzymes.  However, 
several different types of SUMO E3 ligase enzymes have been identified, including members of the 
Siz/PIAS (Protein Inhibitor of Activated STAT) family, nuclear pore protein Nup358 or RanBP2, 
polycomb group protein Pc2, and recently categorized ZNF451 (48-54).  SUMO E3 ligases act as 
catalysts that enhance the transfer of SUMO from charged E2 (E2~SUMO) to the target substrate.  The 
largest group of SUMO E3 ligases, the Siz/PIAS family, is characterized by the presence of an SP-RING 
domain, which is predicted to resemble the RING domain in ubiquitin RING E3 ligases and function in 
an analogous manner (43,46,55).  Members of the Siz/PIAS family include the yeast Siz proteins and 
human PIAS proteins (PIAS1, two variants of PIAS2, PIAS3, and PIAS4/y) that share important 
conserved functional domains (Figure 1-3B).  The N-terminal SAP (scaffold attachment factor-A/B, 
acinus and PIAS) domain of Siz/PIAS ligases is involved in AT-rich DNA binding, the PINIT domain is 
important for substrate recognition, the SP-RING domain related to the ubiquitin RING E3 ligases binds 
E2 Ubc9, and SIM together with the acidic domain at the C-terminus mediates non-covalent SUMO 
binding (Figure 1-3B) (43,52,55,56).  
 
Several SUMO E3 ligases display specificity toward a particular SUMO isoform and even, the 
target substrate.  PIASy (a member of Siz/PIAS E3 ligase family) preferentially conjugates SUMO-2/3 
and not SUMO-1 to mitotic SUMOylation substrates (48,57,58).  However, the molecular basis for this 
SUMO paralog specificity has not been determined.  To gain an understanding of this phenomenon, I 
performed NMR interaction studies of PIASy and SUMO proteins, which lead to an unexpected 
discovery of a novel SUMO-interacting motif (SIM) in PIASy.  The identification, characterization and 




Figure 1-3.  The SUMO conjugation pathway and E3 ligases.  (A) SUMO conjugation requires 
sequential action of SUMO E1 activating, SUMO E2 conjugating, and SUMO E3 ligating enzymes.  
Although SUMO E2 can catalyze conjugation to a substrate in an E3-independent manner through 
recognition of SUMO consensus motifs (ψKXE), E3 ligases often enhance SUMO transfer and can impart 
substrate specificity for directing conjugation to non-consensus lysine residues.  Figure adapted from (43).  
(B) Schematic showing conserved domains of the Siz/PIAS SUMO E3 ligase family: SAP (vertical lines), 
PINIT (solid black), SP-RING (grid), SUMO-interacting motif (SIM, blue), and S/DE (horizontal lines) 




1.4.  The RNA-binding protein HuR 
 
 Posttranscriptional regulation of gene expression is crucial for proper growth and development in 
all organisms.  mRNA decay is one major factor that influences posttranscriptional gene expression 
(59,60).  In mammalian cells, mRNA decay is tightly regulated by specific cis elements present in the 
RNA and trans acting factors.  The most widespread and well-studied instability cis acting elements of 
mRNA decay are represented by the adenine- and uridine-rich elements (AREs) located in the 3’- or 5’-
untranslated regions (UTRs).  The trans acting RNA-binding proteins associate with these cis AREs and 
regulate the fate of target mRNAs (59-62). 
 
1.4.1.  HuR-ARE binding 
 
 The human antigen R (HuR, also called HuA) is among the most widely studied RNA binding 
proteins that bind to AREs of target mRNAs and modulate their stability and translation (59,62).  HuR is 
a member of the Hu/ELAV (embryonic lethal abnormal vision-like) family of RNA-binding proteins.  In 
contrast to the other three family members, namely, HuB, HuC, and HuD, which are exclusively found in 
neuronal tissues, HuR is ubiquitously expressed (59,63).  HuR contains three classic RNA-recognition 
motifs, RRM1, RRM2, and RRM3 that are highly conserved among the family members.  The two 
tandem N-terminal RRM domains, RRM1 and RRM2 (together referred as RRM1/2), are responsible for 
binding and stabilizing AREs contained in mRNAs (59,63,64).  The third RRM, RRM3, is thought to 
bind the poly-A tail, maintain the stability of RNA-protein complex, and is responsible for cooperative 
assembly of HuR oligomers on RNA (65).  The basic hinge region between RRM2 and RRM3 contains a 
nuclear-cytoplasmic shuttling sequence (HNS) that enables HuR to translocate from nucleus to cytoplasm 
(66).  Posttranslational modifications, mainly phosphorylation, by kinases such as, cyclin-dependent 
kinase 1, protein kinase C, and p38 mitogen-activated protein kinase, can influence nucleocytoplasmic 
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transport and mRNA interactions of HuR (67-69).  Crystal structures of free and ARE-bound HuR 
RRM1/2 are available, which indicate distinct open and close conformations of HuR RRM1/2, 
respectively (64). 
 
1.4.2.  HuR and Cancer 
  
 A number of cancer-related transcripts, including mRNAs of proto-oncogenes, growth factors, 
and cytokines, contain AREs, which confer a short mRNA half-life (59,60).  Many of these mRNAs have 
been characterized as HuR targets (59,67,69).  Binding of HuR to the AREs of these cancer-associated 
mRNAs generally lead to mRNA stabilization and increased translation.  HuR has been shown to promote 
tumorigenesis by enabling multiple cancer phenotypes (Figure 1-4) (67,69).  HuR regulated oncogenic 
mRNAs encode proteins that are implicated in different tumor processes, such as, cell proliferation, cell 
survival, reduced immune recognition, angiogenesis, invasion, and metastasis (Figure 1-4).  HuR is 
overexpressed in a wide variety of cancer.  High levels of cytoplasmic HuR have been found in colorectal, 
gastric, lung, breast, ovarian, pancreas, and skin carcinoma (67-72).  Elevated cytoplasmic accumulation 
of HuR correlates with high-grade malignancy and serve as a prognostic factor of poor clinical outcome 
in those cancers (67,69-72).  In a mouse xenograft model, injection of carcinoma cells with elevated HuR 
produced significantly larger tumors than control population, and reduction in HuR expression through 
RNA interference resulted in a significant decrease in tumor size (70).  Taken together, HuR presents an 





Figure 1-4.  HuR regulated mRNAs implicated in establishing cancer traits.  The target mRNAs of 
HuR are involved in all major cancer-acquired phenotypes, including cell proliferation, cell survival, 
reduced immune recognition, angiogenesis, invasion, and metastasis.  Figure from (67). 
 
I hypothesized that drugs that interfere with HuR-ARE interaction or disrupt the stabilizing effect 
of HuR upon mRNA targets could  have dramatic effects on inhibiting cancer cell growth and 
progression (74).  In this dissertation, using fluorescence polarization based screening, a fungal natural 
product was identified as an inhibitor of HuR-ARE interaction.  I used NMR methods to validate and 
characterize small molecule and ARE binding to HuR.  The inhibition and molecular interactions studies 
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2.1.  Abstract 
 
Many Gram-negative pathogens, such as Shigella, Salmonella, Yersinia, and Pseudomonas, 
assemble the type III secretion system (T3SS) to inject virulence proteins directly into eukaryotic cells to 
initiate infectious diseases.  The needle apparatus of the T3SS consists of a base, an extracellular needle, a 
tip protein complex, and a translocon.  The atomic structure of the assembled tip complex and the 
translocon is currently unknown.  Here, we show by NMR chemical shift mapping and paramagnetic 
relaxation enhancement (PRE) that the mixed α-β domain at the distal region of the Shigella tip protein 
IpaD interacts with the N-terminal ectodomain of the major translocon protein IpaB.  Furthermore, 
incorporation of the extreme N-terminal residues of the translocon protein IpaB, previously thought to be 
important for the IpaD-IpaB interaction, had little change on the NMR-observed interaction.  Our results 
reveal the binding surfaces involved in the tip–translocon protein–protein interaction and provide insight 
into the assembly of the needle apparatus of the T3SS. 
 
 
2.2.  Introduction 
 
The T3SS plays a critical role in the pathogenesis of many Gram-negative bacteria, including the 
causative agent of bacillary dysentery, Shigella flexneri (1,2).  To initiate infection, Shigella assembles 
the T3SS to inject virulence proteins directly into the target host cells (3).  The needle apparatus of the 
T3SS consists of a base that spans the bacterial membranes (4-6), an external needle (7,8), and at the 
needle tip, a complex of an estimated 4-5 copies of the tip protein IpaD (in Shigella T3SS) (9).  Upon host 
cell contact, the tip complex serves as a platform for the assembly of the translocon, which forms a pore 
in the host cell membrane that allows the passage of effector proteins directly into the host cell cytoplasm 
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(10).  The atomic structure of the assembled tip complex and the translocon is currently unknown and 
how the tip protein interacts with the translocon protein is poorly understood. 
 
 The crystal structure of the tip protein IpaD shows an overall oblong shape with a long central 
coiled-coil juxtaposed to a N-terminal -helical hairpin and a distal domain consisting of mixed 
helices and sheets (mixed  domain) (Figure 2-1) (11,12).  The translocon is assembled from the 
major and minor translocon proteins (the qualifiers refer to their relative sizes; both are essential in the 
type III secretion).  IpaB and IpaC are the major and minor translocon proteins of Shigella, respectively 
(4).  The major translocon protein IpaB possesses structural features, such as, an N-terminal cytosolic 
ectodomain, a central hydrophobic region with two predicted transmembrane helices, and a C-terminal 
amphipathic region (13,14).  The atomic structure for any full-length translocon protein is currently 
unknown, however, crystal structure of the N-terminal ectodomain of IpaB shows an helical trimeric 
antiparallel coiled-coil motif (Figure 2-1) (15).  
 
 Dickenson et al. (16) reported interaction between the IpaD and the N-terminal ectodomain of 
IpaB (residues 1-226) by FRET and showed that the interaction required presence of the bile salt 
deoxycholate (DOC) and that IpaB residues 11-27 were essential for the interaction.  Here, we used NMR 
chemical shift mapping and paramagnetic relaxation enhancement (PRE) methods to identify the surfaces 
involved in the IpaD-IpaB protein-protein interaction.  Our results indicate that the surface around the 
mixed  domain of the IpaD is involved in the interaction with the N-terminal domain of IpaB.  





Figure 2-1.  Crystal structure of IpaB74-224 and IpaD38-322.  (A) The positions of the spin labels on IpaB 
used in the PRE studies are shown as black spheres.  (B) Different domains of IpaD are colored as 
follows: N-terminal hairpin, gray; central coiled-coil, cyan; and distal mixed  region, green.  
 
 
2.3.  Methods 
 
2.3.1.  Protein expression and purification   
 
IpaD (residues 38-332) wild type (referred as IpaD) and C322S mutant (referred as IpaDC322S) 
were subcloned in the NdeI/SalI sites of a modified pET-21a expression vector.  The IpaD construct 
contained an N-terminal His6-tag followed by a tobacco etch virus (TEV) protease cleavage site.  DNA 
corresponding to IpaB76-308, IpaB74-224, and IpaB9-226 were PCR amplified and subcloned into the 
NdeI/XhoI sites of pET-22b.  The IpaB constructs retained a non-cleavable C-terminal LEH6 tag for 
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protein purification.  Plasmids were freshly transformed in E. coli BL21 (DE3) and cells were grown in 1 
L culture media containing 100 g/ml carbenicillin.  Unlabeled proteins were expressed in LB broth and 
15N-labeled proteins were obtained by cell growth in M9 minimal media supplemented with 1 g of 15N-
ammonium chloride.  Bacteria were grown at 37 oC, induced with 1 mM isopropyl--D-
thiogalactopyranoside (IPTG) at OD600 ~ 0.7-0.8, and cell growth was continued overnight at 15 oC.  Cells 
were harvested by centrifugation and cell pellets were resuspended in 30 ml binding buffer (500 mM 
NaCl, 20 mM Tris-HCl pH 8.0, 5 mM imidazole).  Cells were lysed by sonication in the presence of 0.1 
mM phenylmethanesulfonylfluoride (PMSF).  Cellular debris was removed by centrifugation at 13,000 
rpm for 10 min, and 600 l of 5% (v/v) polyethyleneimine was added to the supernatant to precipitate the 
nucleic acids.  Following centrifugation (13,000 rpm, 10 min), the clear supernatant was loaded on a ~5 
mL Ni2+-affinity chromatography resin (Gold Biotechnology) and the Ni2+ column was washed with 100 
ml binding buffer, followed by elution with 50 ml elution buffer (500 mM NaCl, 20 mM Tris-HCl pH 8.0, 
250 mM imidazole).  Fractions containing IpaD, were incubated overnight at room temperature with 250 
l of 0.04 mM recombinant TEV protease (17) in buffer (20 mM NaCl, 20 mM Tris-HCl pH 8.0, 0.5 mM 
EDTA, and 1 mM DTT) and the digest was passed through a Ni2+ column to separate the protein from the 
His6-tag.  IpaD retained a 3-residue ‘GHM’ cloning artifact.  Purified proteins were dialyzed in NMR 
buffer (100 mM NaCl, 20 mM sodium phosphate pH 7.0) and concentrated using Amicon Ultra 10K 
centrifugal filter (Millipore) and protein concentrations were estimated by absorbance at A280. 
 
2.3.2.  15N-amino acid-specific labeling of IpaD   
 
15N-leucine labeling was used in the PRE studies.  The 15N-leucine labeled IpaD was prepared 
following the published protocol with minor modification (18).  Briefly, cells expressing IpaD from 
overnight 1 L LB culture were harvested and resuspended in 2X 500 ml M9 minimal media.  The media 
was supplemented with 125 mg of 15N-leucine and 300 mg of the remaining 19 unlabeled amino acids.  
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The starting OD600 was kept around 0.6-0.8 and cells were grown at 37 oC for 10 minutes followed by 
induction with 1 mM IPTG.  Cell growth was continued for 4 hours at 37 oC or until OD600 was ~ 2.6 to 
3.0.  Recombinant proteins were purified as described above. 
 
2.3.3.  Engineering of cysteine mutations in IpaB74-224 for spin labeling   
 
Several non-conserved polar residues that are expected to be surface exposed in IpaB74-224 were 
mutated into cysteine for the attachment of the spin label for PRE measurements.  QuikChange site-
directed mutagenesis was used to generate eight cysteine mutants in IpaB74-224 residues Ser-77, Asn-85, 
Gln-109, Lys-115, Asn-142, Asn-156, Gln-201, and Ser-205 (Figure 2-1).  All mutations were confirmed 
by DNA sequencing.  The cysteine mutant proteins were expressed and purified following the protocol 
described above.  The purified cysteine-containing IpaB74-224 protein was dialyzed in NMR buffer 
containing 5 mM DTT to prevent the formation of intermolecular disulfide bonds. 
 
2.3.4.  Spin labeling of IpaB74-224 
 
A nitroxide spin label, MTSL (1-Oxyl-2,2,5,5-tetramethyl-3-pyrroline-3-methyl) 
methanethiosulfonate (Toronto Research Chemicals) was conjugated to the cysteine mutants of IpaB74-224 
following our published protocol (19).  Briefly, 10 mg of MTSL was dissolved in 250 μl of acetone to 
make a 150 mM stock solution that was added at 7-fold molar excess to the protein for labeling.  The 
extent of MTSL labeling was confirmed by ESI-MS.  
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2.3.5.  Circular dichroism spectroscopy   
 
CD spectra were acquired with a JASCO J-815 spectropolarimeter.  Proteins were diluted to a 
final concentration of 1-2 μM in buffer (5 mM NaCl, 5 mM sodium phosphate pH 7.0).  Spectra were 
acquired in triplicate at 20 oC with a scan rate of 50 nm/min.  Thermal denaturation curves were acquired 
by monitoring the molar ellipticity at 222 nm over a temperature range of 20 oC to 80 oC with a 
temperature ramp rate of 2 oC/min. 
 
2.3.6.  NMR spectroscopy   
 
NMR data were acquired on a Bruker Avance 800 MHz spectrometer equipped with a cryogenic 
triple-resonance probe, processed by NMRPipe (20), and analyzed using NMRView (21).  Two-
dimensional 1H-15N TROSY spectra were acquired using 0.2 mM 15N-labeled IpaB74-224 or 15N-labeled 
IpaD (wild type or C322S mutant) in buffer (100 mM NaCl, 10 mM sodium phosphate pH 7.0, 10% D2O) 
at 30 oC.  PREs were measured by single time-point method (22).  For PRE data acquisition, two 2D 1H-
15N HSQC spectra were acquired on two NMR samples with identical NMR acquisition parameters.  The 
first 2D 1H-15N TROSY spectrum was acquired using an 15N-Leu labeled IpaD complexed with 
paramagnetic (or MTSL-spin labeled) IpaB74-224.  A second 2D 1H-15N TROSY spectrum was acquired 
using 15N-Leu labeled IpaD complexed with diamagnetic IpaB74-224.  The protein concentrations, buffer 
conditions, acquisition and processing parameters were kept identical for the paramagnetic and 
diamagnetic NMR samples to ensure that the observed intensity changes were only due to the effect of the 
spin label on the tip protein.  Typical PRE samples contained 0.4 mM 15N-leucine IpaD mixed with 0.4 
mM (paramagnetic or diamagnetic) IpaB74-224 in PRE buffer (100 mM NaCl, 20 mM sodium phosphate 
pH 7.0, 10% D2O) and the data were acquired at 32 oC.  Published backbone amide assignments of IpaD 
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were used in the analysis (23).  Residues perturbed during the binding studies were mapped onto the 
crystal structure of IpaD (PDB ID 2J0O) (12). 
 
 
2.4.  Results 
 
2.4.1.  Expression and purification of protein constructs for NMR studies  
 
IpaD constructs were expressed and purified under native conditions.  IpaD was well behaved in 
solution and has been previously characterized by NMR (23).  The IpaB constructs, IpaB76-308 and IpaB74-
224, were designed based on the proteolysis data (24), crystal structures (15), and the known chaperone 
binding sites (25-27).  Purified IpaB76-308 showed limited stability and solubility, whereas IpaB74-224 
showed better behavior in solution and was more amenable for NMR studies and thus used for the PRE 
studies.  To test the significance of the extreme N-terminal residues of IpaB in the IpaD-IpaB protein-
protein interaction (16), a longer IpaB construct, IpaB9-226 was subcloned, expressed and purified under 
native conditions similar to the shorter IpaB constructs. 
 
2.4.2.  NMR spectroscopy on the major translocon protein IpaB   
 
NMR spectroscopy was used to gain insights into the solution behavior of IpaB constructs.  The 
2D 1H-15N TROSY spectrum of IpaB74-224 at 37 oC displayed overall good dispersion, but peaks were 
broad and poorly resolved (Figure 2-2A).  Increasing the acquisition temperature to 47 oC significantly 
improved the NMR spectrum of IpaB74-224 (Figure 2-2B).  The peaks were distinct, sharp, and well 
resolved, however, only ~65-70% of the residues from the protein were represented in 2D 1H-15N TROSY 
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spectrum of IpaB74-224, thus backbone assignment of IpaB74-224 by 3D NMR would have been challenging 
and not carried out.  Because the backbone resonances of the tip protein IpaD have already been assigned 
(23), and the translocon protein constructs gave less than ideal NMR spectra as shown above (Figure 2-2), 
we used 15N-labeled IpaD with spin-labeled IpaB (or unlabeled IpaB) to characterize the tip-translocon 




Figure 2-2.  NMR spectroscopy on the N-terminal ectodomain of the major translocon protein IpaB.  
2D 1H-15N TROSY spectra of (A) IpaB74-224 at 37 oC, and (B) IpaB74-224 at 47 oC.      
 
2.4.3.  Generation of IpaB74-224 cysteine mutants for spin labeling   
 
PRE measurements require attachment of paramagnetic spin labels at various positions.  The site-
directed spin labeling was achieved by engineering cysteine residues in specific locations on IpaB74-224.  A 
total of eight cysteine point mutations in IpaB74-224 were created for the attachment of the MTSL spin 
label (Figure 2-1A).  CD spectroscopy was used to assess the folding of the cysteine mutants and to 
ensure that the MTSL conjugation did not alter the overall secondary structure of the proteins.  All the 
cysteine mutants before and after the attachment of MTSL spin label displayed CD spectra similar to the 
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wild type construct (Figure 2-3).  The extent of the spin labeling was confirmed by ElectroSpray 
Ionization Mass Spectrometry (ESI-MS) to be 100% with the expected mass increase of 185 Da upon 




Figure 2-3.  CD spectroscopy of IpaB74-224 cysteine mutants used in the PRE studies.  (A-H) The CD 
spectrum of wild type IpaB (WT) compared with cysteine point mutants before and after attachment of 




Figure 2-4.  Representative electrospray ionization mass spectrometry (ESI-MS) on IpaB and IpaD 
proteins to confirm the extent of labeling.  ESI-MS on IpaB N85C mutant (A) before MTSL-labeling 
(theoretical mass, 18479 Da), and (B) after MTSL labeling (theoretical mass, 18664).  MTSL conjugation 
resulted in an expected increase in mass of 185 Da.  (C) ESI-MS of 15N-Leu labeled IpaD (theoretical 
mass, 33186).   
 
2.4.4.  PRE of 15N-amino acid-specifically labeled IpaD with spin-labeled IpaB  
 
 IpaD (298 amino acids) is a large protein making the PRE analysis complicated.  To reduce the 
complexity of the NMR datasets and enable the determination of subtle reductions in peak intensities 
upon protein-protein interaction, 15N-leucine labeled IpaD was used in the PRE study.  The leucine 
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residues of IpaD are distributed throughout the protein and provide coverage around all three domains: 
the N-terminal hairpin, the central coiled-coil, and the mixed  region.  Corresponding to the 35 
leucines present in the IpaD construct, selective 15N-leucine labeling resulted in an increase of mass by 35 
Da (33151 + 35 = 33186 Da, Figure 2-4).  An optimal molar titration ratio of 1:1 for IpaD:IpaB was 
chosen for the PRE experiments on the basis of the extent of peak broadening observed at higher titration 
ratios (data not shown).  PRE measurements were carried out by single time-point method (22).  IpaD 
residues that lie close to the spin label should experience high PRE effect and show reduction in peak 
intensity in the paramagnetic datasets when compared to the control diamagnetic datasets (Ipara/Idia < 1).  In 
contrast, IpaD residues residing away from the spin label should remain unaffected (Ipara/Idia ~1).  
Representative 2D NMR spectra used in the PRE determination for 15N-Leu IpaD titrated with IpaB74-224 





Figure 2-5.  Representative 2D 1H-15N TROSY spectra of IpaD used in the PRE determination.  15N-
Leu IpaD complexed with (A) diamagnetic and (B) paramagnetic IpaB74-224 N85C.  Arrows point to the 
residues that showed reduction in peak intensity in the presence of spin label.  Peaks marked with an 
asterisk were visible at a lower contour level. 
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2.4.5.  PRE of Shigella IpaD-IpaB74-224 interaction   
 
Spin labels attached on IpaB74-224 at positions Asn-156, Asn-142, Gln-201, Ser-205, and Ser-77 
essentially resulted in weak to moderate PRE effect on IpaD (Figure 2-6).  With the exception of Leu-70 
of IpaD, majority of the residues gave an Ipara/Idia ratio above 0.7 (Figure 2-6A).  Of these spin label 
positions, position Asn-156 displayed weakest PRE with a large number of peaks showing an Ipara/Idia ratio 
of ~1.  Spin labels positioned at Asn-85, Gln-109, and Lys-115 (clustered towards the top N-terminal 
region of IpaB in the crystal structure, Figure 2-6B) produced strongest PRE effect on specific IpaD 
residues.  Leu-70, Leu-202, Leu-211, and Leu-260 of IpaD experienced strongest PRE with Ipara/Idia values 
between 0.3-0.55 and Leu-199, Leu-227, Leu-257, and Leu-311 experienced moderate PRE with Ipara/Idia 
of ~0.6 (Figure 2-6A).  Spin labels close to the N-termini of IpaB74-224 produced highest PRE effect and 
as the labels were moved down towards the end of the coiled-coil, PRE effect was minimized (Figure 2-
6).  Irrespective of the spin label position, Leu-70 of IpaD gave highest PRE that could be due to its 
location on a highly flexible loop region.  The affected residues mapped largely near the mixed  
region of IpaD (Figure 2-6C).  A detailed analysis of PRE effects with individual spin-label sites has 
been shown in Figure 2-7.  Our PRE results indicate that region around the mixed  domain of IpaD is 




Figure 2-6.  PRE results of 15N-Leu IpaD and spin-labeled IpaB74-224.  (A) Each panel corresponds to 
one spin label position of IpaB74-224.  Circles in each panel represent Ipara/Idia intensity ratio for leucine 
residues of IpaD.  The gray line at Ipara/Idia intensity ratio of 1.0 is taken as having no PRE effect.  L70, 
L202, L211, and L260 of IpaD (labeled in red) experienced the strongest PRE effect.  (B) The position of 
the spin labels (spheres) in IpaB74-224 are colored based on the strength of the PRE as strong (red), 
moderate (yellow), and weak or none (gray).  Spin label positions yielding strong PRE on IpaD (N85, 
Q109, K115) are clustered on the top N-terminal region of IpaB.  (C) Results of PRE mapped onto the 
structure of IpaD.  IpaD leucine residues that experienced the strongest PRE effect (Ipara/Idia < 0.6) are 
colored red, residues showing moderate PRE (Ipara/Idia ~ 0.6-0.69) are orange, weak (Ipara/Idia ~ 0.7-0.79) 
are yellow, and almost no effect (Ipara/Idia > 0.8-1.0) are white.  Unassigned leucines are colored light blue.  





Figure 2-7.  PRE effect produced by individual spin label positions in IpaD-IpaB interaction.  
Results of the PRE experiments with spin-labeled IpaB74-224 mapped onto the structure of IpaD. Color 
scheme is followed from Figure 2-6. 
 
2.4.6.  Role of extreme N-terminal residues of IpaB and bile salt DOC in IpaD-IpaB interactions   
 
We tested a longer IpaB fragment encompassing extreme N-terminal residues (IpaB 9-226) that 
were previously shown to be important for the IpaD-IpaB binding (16).  15N and ILV labeled IpaDC322S 
was titrated with unlabeled IpaB9-226 and the titrations were monitored by acquiring 2D 1H-15N TROSY 
and 2D 1H-13C HSQC experiments.  Stepwise addition of unlabeled IpaB9-226 to IpaDC322S resulted in a 
concentration dependent decrease in the peak intensities of specific IpaDC322S backbone amide (Figure 2-
8A) and side chain ILV methyl resonances (Figure 2-9A).  Importantly, there were residues that did not 
undergo signal broadening; even at the highest IpaDC322S:IpaB9-226 titration ratio indicating the complex 
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formation did not result in protein aggregation.  The intensity ratio (I1:1/I1:0 in amide titrations; and 1-
I1:1/I1:0 in ILV titrations) for each non-overlapped IpaDC322S residue at an IpaDC322S:IpaB9-226 ratio of 1:1 
was plotted to identify the tip residues that were perturbed the most upon addition of IpaB9-226 (Figure 2-
8B and 2-9B) and mapped onto the crystal structure of IpaD (Figure 2-8C and 2-9C).  In both backbone 
amide and side chain ILV methyl titrations, the affected residues clustered in the distal region of IpaD, 




Figure 2-8.  Presence of extreme N-terminal residues of IpaB did not alter the surfaces of IpaD 
involved in the binding of IpaB as detected by amide titrations.  (A) Overlay of four 2D 1H-15N 
TROSY spectra of 15N-labeled IpaDC322S with increasing concentrations of unlabeled IpaB9-226.  (B) Plot 
of peak intensity ratio of complex (I1:1) vs free form (I1:0) for IpaDC322S:IpaB9-226 complex with the average 
peak intensity ratio shown as gray line and one standard deviation from the average, 1 shown as red 
line.  (C) Residues with peak intensity ratio (I1:1/I1:0) lower than 1 mapped onto the crystal structure of 





Figure 2-9.  Extreme N-terminal residues of IpaB did not alter IpaD-IpaB interaction surfaces as 
detected by ILV methyl titrations.  (A) Overlay of five 2D 1H-13C HSQC spectra of 13C-ILV-labeled 
IpaDC322S with increasing concentrations of unlabeled IpaB9-226.  (B) Peak intensity ratio of complex (I1:1) 
vs free form (I1:0) for IpaDC322S:IpaB9-226 complex plotted as a difference from peak intensity ratio of 1.  
Average peak intensity ratio is shown with a gray line and one standard deviation from the average, 1 
shown as red line.  (C) Residues with peak intensity ratio (1-I1:1/I1:0) greater than 1 mapped onto the 
crystal structure of IpaD and shown in red. 
 
 
 Furthermore, bile salt DOC was reported to be essential for the interaction between IpaD and N-
terminal ectodomain IpaB (16).  To test this, we titrated 15N and ILV labeled IpaDC322S with unlabeled 
IpaB9-226 in the presence of 0.4 mM DOC.  Similar to the titration in the absence of DOC (Figure 2-8 and 
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2-9), we observed a concentration dependent decrease in the peak intensity of IpaD resonances in the 
presence of DOC (Figure 2-10A and 2-11A).  Analysis of the peak intensity ratio in the presence of 
DOC at a 1:1:2 molar ratio (Figure 2-10B and 2-11B) showed that the affected IpaD residues were 
primarily clustered at the distal region (Figure 2-10C and 2-11C).  Together, this suggests that DOC did 
not largely alter the affected IpaD and IpaB interaction surface or modulate the protein affinity as 
observed by NMR. 
 
2.5.  Discussion 
 
 An important step in type III secretion is the assembly of the translocon on the tip complex.  The 
protein-protein interactions between the tip and the translocon proteins are crucial for the attachment of 
the bacterium to the host cell membrane and the delivery of effector proteins through the translocon pore 
(28-30).  However, the atomic details of the protein-protein interaction governing the assembly of the tip-
translocon structure remain poorly understood.  The current hypothesis in the literature is that IpaD and 
IpaB form a heteropentameric complex consisting of 4 copies of IpaD and 1 copy of IpaB at the needle tip 
(31-33), and this IpaD:IpaB interaction is essential for host cell sensing, assembly of the translocon pore, 




Figure 2-10.  Significance of the bile salt DOC in IpaD-IpaB interaction.  (A) Overlay of three 2D 1H-
15N TROSY spectra of 15N-labeled IpaDC322S with increasing concentrations of unlabeled IpaB9-226 in the 
presence of 0.4 mM DOC.  (B) Plot of peak intensity ratio of complex (I1:1) vs free form (I1:0) for 
IpaDC322S:IpaB9-226 complex in presence of 0.4 mM DOC.  The average peak intensity ratio is shown as 
gray line and one standard deviation from the average, 1as red line.  (C) Residues with peak intensity 





Figure 2-11.  Bile salt DOC did not alter the IpaD-IpaB interaction surface.  (A) Overlay of five 2D 
1H-13C HSQC spectra of 13C-ILV-labeled IpaDC322S with increasing concentrations of unlabeled IpaB9-226 
in the presence of 0.4 mM DOC.  (B) Peak intensity ratio of complex (I1:1) vs free form (I1:0) for 
IpaDC322S:IpaB9-226 complex in presence of 0.4 mM DOC plotted as a difference from peak intensity ratio 
of 1.  The average peak intensity ratio is shown as gray line and one standard deviation from the average, 
1as red line.  (C) Residues with peak intensity ratio (1-I1:1/I1:0) greater than 1 mapped onto the crystal 




There are conflicting results regarding the role of the bile salt DOC in triggering the presentation 
of IpaB at the tip complex.  While several studies indicate exposure of IpaD to the bile salt deoxycholate 
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is needed for the recruitment of IpaB at the tip (16,34,35), others have shown the association of IpaD and 
IpaB at the needle tip without the need for DOC (32,33,36).  Dickenson et al. (16) used fluorescence 
polarization and FRET assays to show that IpaD interacts with the N-terminal fragment of IpaB, and that 
the IpaD-IpaB interaction was detected only in the presence of high concentrations of DOC.  Results of 
our NMR titrations and PRE studies presented here indicate that IpaB ectodomain interact with the 
cognate tip protein IpaD in the absence of deoxycholate and inclusion of extreme N-terminal residues of 
IpaB or DOC does not alter the IpaD-IpaB binding.  
 
 Results of fluorescence spectroscopy and NMR chemical shift mapping (Figure 2-12) show weak 
binding affinity at M range between IpaD and IpaB (16).  Such weak interactions probably provide these 
proteins sufficient conformational flexibility to perform their multi-functional roles in host environment 
sensing, translocon assembly, or for switching the system to an ‘actively secreting’ state.  To gain insights 
into this weak interaction, we complemented the NMR chemical shift mapping with sensitive PRE 
methods, which requires paramagnetic spin labels that are conjugated to the protein through cysteine 
residues.  Nuclear dipoles within ~15-20 Å of the spin label undergo increased relaxation, resulting in the 
reduction of the peak intensities of the residues lying close to the spin label.  We engineered eight IpaB74-
224 cysteine mutants to attach the spin label and confirmed by CD spectroscopy that the cysteine mutation 
and the MTSL spin label did not alter the global fold of the proteins.  Together our NMR and PRE results 




Figure 2-12.  Characterization of IpaD-IpaB74-224 interaction by NMR chemical shift mapping.  (A) 
Overlay of four 2D 1H-15N TROSY spectra of 15N-labeled IpaD with increasing concentrations of 
unlabeled IpaB74-224.  (B) Plot of peak intensity ratio of complex (I1:1) vs free form (I1:0) for IpaD:IpaB74-224 
complex with the average peak intensity ratio shown as gray line and one standard deviation from the 
average, 1 shown as red line.  (C) Residues with peak intensity ratio (I1:1/I1:0) lower than 1 mapped 
onto the crystal structure of IpaD and shown in red. 
 
 Our results on the tip-translocon interaction are consistent with the previous results of Johnson et 
al. (12) showing that deletion of the mixed domain of IpaD (residues 192 to 267) abolishes the 
localization of IpaB on the needle tip.  The recent EM model of the Shigella tip-translocon complex, 
albeit at low resolution, shows that the mixed domain of IpaD faces outside and lie close to the 
observed density for IpaB on the assembled tip (32).  Additionally, the recent crystal structure of AopB 
(the homolog of IpaB in Aeromonas) indicates that the N- and C-terminal domains of AopB remain on the 
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extracellular portion upon membrane insertion, making these domains potential candidates for protein-
protein interaction with the tip protein (37).  Incorporating these with our previous results that the needle 
protein binds at the proximal end (or lower portion of the coiled-coil domain as depicted in Figure 2-1) of 
the tip protein (19,38), we propose a model where the N-terminal ectodomain of IpaB acts as an anchor to 
attach to the distal end of the tip protein IpaD at the mixed domain, while the proximal end of the tip 




Figure 2-13.  Model of the tip-translocon interaction.  (A) Predicted membrane topology for the major 
translocon protein IpaB.  (B) Proposed model for the interaction between the distal region of IpaD and the 
N-terminal ectodomain of IpaB in the assembly of the T3SS needle apparatus.  The tip complex is 
represented based on the EM model of Shigella tip with the central coiled-coil domain shown in blue and 
the mixed  region in green. 
 
In summary, our NMR binding studies confirmed a direct protein-protein interaction between the 
tip protein IpaD and the major translocon protein IpaB of Shigella in the absence of deoxycholate.  
Further, we have localized the interaction interface to the N-terminal cytosolic domain of IpaB and the 
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distal end of the tip protein IpaD.  Similar studies performed on SipD-SipB, the IpaD-IpaB homologs in 
Salmonella also revealed that the distal region of SipD is involved in binding the N-terminal ectodomain 
of SipB.  This suggests that the tip-translocon protein-protein interaction surfaces are conserved between 
Shigella and Salmonella.  Our findings provide new insight into the interactions involved in the assembly 
of the T3SS needle apparatus. 
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3.1.  Abstract 
 
The rapid and alarming rise of antibiotic resistance in pathogens requires new targets for 
developing novel anti-infectives.  The type III secretion system (T3SS) is essential in the pathogenesis of 
many medically important pathogens and represents an attractive target for the development of new 
antibiotics.  Yersinia and Pseudomonas, the causative agents of plague and nosocomial infections, along 
with many other Gram-negative bacteria rely on the T3SS to inject virulence proteins directly into 
eukaryotic cells to initiate infection.  An important step in rational design of anti-virulence drugs targeting 
T3SS is the identification of small molecules that can bind to T3SS proteins.  LcrV and PcrV, the tip 
proteins from the Yersinia and Pseudomonas T3SS are critical virulence proteins and known protective 
antigens.  In this study, through a surface plasmon resonance screen of 288 small and diverse fragments, 
we identified the binding of 5-hydroxyindole and 4-(4-methylpiperazino)aniline to LcrV, 3-amino-7-
bromoquinoline to PcrV, and 3-(1H-pyrrol-1-yl)benzo[b]thiophene-2-carboxylic acid to both LcrV and 
PcrV.  Further, NMR methods were utilized to characterize and identify the surface on tip proteins 
involved in the small molecule interaction.  Our results demonstrate that LcrV and PcrV are promising 
druggable targets and the identified molecular fragments can potentially be used for the development of 
novel T3SS inhibitors. 
 
 
3.2.  Introduction 
 
The type III secretion system (T3SS) is indispensable for virulence of a wide spectrum of 
clinically relevant bacterial pathogens, including Yersinia pestis, the etiologic agent of plague, 
Pseudomonas aeruginosa, the causative agent of secondary hospital infections, and other Gram-negative 
bacteria, such as, Salmonella, Shigella, and Chlamydia spp (1).  With ever-increasing incidence of 
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antibiotic resistance in these pathogens, there is a pressing need for the development of new anti-
bacterials (2,3).  Targeting the virulence factors of pathogenic bacteria, rather than their survival, provides 
a promising alternative to the use of traditional bactericidal antibiotics.  Since the T3SS is a major 
virulence determinant of many Gram-negative bacteria and exposed on the bacterial surface, disrupting 
the T3SS is an attractive target for developing novel anti-virulence drugs (2-5). 
 
 Bacterial pathogens utilize the T3SS to inject virulence effector proteins into their target host 
cells to initiate infectious diseases (6).  The T3SS is composed of structural and nonstructural proteins (7).  
The structural component of the T3SS, the needle apparatus, is assembled from more than a dozen 
different proteins and consists of a base that spans the bacterial membranes, an external needle, and a tip 
complex.  Upon host cell contact, a translocon is assembled between the needle tip complex and the host 
cell, which creates a pore in the host cell membrane and provides a gateway for translocation of effector 
proteins (8).  The multi-functional tip proteins forming the needle tip complex are crucial for the bacterial 
virulence and responsible for host cell sensing, assembly of the translocon pore, and regulation of the 
secretion of effector proteins into the host cells (7,9).  LcrV and PcrV (together referred as V-proteins) are 
the tip proteins belonging to the ‘Ysc’ family of the Yersinia and Pseudomonas T3SS, respectively (9,10).  
The crystal structure of LcrV is available and displays an overall dumbbell shape with an N-terminal 
globular domain, an elongated central coiled-coil, and a less-structured distal region (11,12).  Although 
the structure of PcrV is currently not known, the I-TASSER model (13) show structural similarity to the 
homolog LcrV.   
 
 Both LcrV and PcrV are potent protective antigens and active or passive immunization against 
these V-proteins provides a high level of protection against T3SS-mediated lethal Y. pestis and P. 
aeruginosa infections (3,9,14).  Indeed, vaccines based on these proteins are currently under various 
stages of development (3,9).  Furthermore, for the past few years, tremendous efforts are being made to 
discover small molecule compounds that inhibit the virulence of Yersinia and Pseudomonas (15-20).  
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Although these compounds inhibit the T3SS, the mechanism of action and specific molecular targets 
within the T3SS for a vast majority remain unknown (4,5).  Here, we show results of a surface plasmon 
resonance (SPR)-based fragment screening of 288 compounds that identified novel small molecule 
fragments that directly bind to the virulent V-proteins (Figure 3-1 and Figure 3-2).  Binding of the hit 
fragments to their cognate protein was further validated and characterized using both ligand and protein-
observed NMR methods.  This is the first report of small molecule fragments that are shown to bind to 
LcrV and PcrV and could be used as potential scaffolds for future drug design.  
 
 
3.3.  Methods 
 
3.3.1.  Expression and purification of LcrV and PcrV   
 
The cloning, expression and purification of LcrV (residues 28-322, C273S) and PcrV (residues 
25-294) have been previously described (11,21).  Both constructs contained an N-terminal His6-GB1 
solubility tag followed by a tobacco etch virus (TEV) protease cleavage site.  The expression plasmids 
were freshly transformed into E. coli BL21 (DE3) cells and grown in culture media containing 100 g/mL 
carbenicillin.  Unlabeled proteins for SPR screening were obtained by cell growth in 1 L of lysogeny 
broth (LB).  For NMR studies, in addition to the traditional 15N-labeling, proteins were simultaneously 
13C-labeled at the side chain ILV methyl groups (13C labeling at C1 methyl group of Isoleucine, geminal 
C of Leucine, and C of Valine).  ILV and 15N-labeled LcrV (or PcrV) were obtained by cell growth in 1 
L of M9 minimal media supplemented with 1 g of 15N-ammonium chloride and 3 g of glucose.  Cells 
were grown at 37°C until OD600 ~0.4 at which the growth medium was supplied with 60 mg of 2-
ketobutyric acid-4-13C (Sigma #571342) to 13C label the C1 isoleucine and 100 mg of 2-keto-3-(methyl-
13C)-butyric acid-4-13C  (Sigma #571334) to label C leucine and C valine methyl groups.  For backbone 
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amide and side chain ILV methyl assignments, perdeuterated LcrV was prepared by cell growth in M9 
minimal media in 1 L of D2O.  For the backbone amide assignments, uniform 15N/13C-labeled 
perdeuterated LcrV was obtained by supplementing media with 1 g of 15N-ammonium chloride and 2 g of 
either non-deuterated 13C-D-glucose (U-13C6) or fully deuterated 13C-D-glucose (U-13C6; 1,2,3,4,5,6,6-d7).  
For the assignment of ILV methyl resonances, 15N/ILV-labeled perdeuterated LcrV was prepared by 
supplying 1 g of 15N-ammonium chloride, 2 g of deuterated D-glucose (1,2,3,4,5,6,6-d7, Cambridge 
Isotope Laboratories, CIL, #DLM-2062), and appropriate 13C ILV keto acids (as described above).  At an 
OD600 of  ~0.7, the culture was induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG).  Cell 
growth was continued overnight in a 15°C shaker to a final OD600 of ~2.8 (~2.0 for D2O-based 
preparations).   
 
 Cells were harvested by centrifugation (4000 rpm, 10 min), resuspended in binding buffer (30 ml; 
500 mM NaCl, 20 mM Tris-HCl pH 8.0, 5 mM imidazole), and lysed by sonication in the presence of 0.1 
mM phenylmethanesulfonylfluoride (PMSF).  Cellular debris was removed by centrifugation (13,000 rpm, 
10 min), and 600 l of 5% (v/v) polyethyleneimine (PEI) was added to the supernatant to precipitate the 
nucleic acids.  After centrifugation (13,000 rpm, 10 min), the supernatant was loaded onto a Ni2+-affinity 
column.  The column was washed with binding buffer and the proteins were eluted with elution buffer 
(500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole).  To remove the tag, fractions containing 
His6-GB1-LcrV (or His6-GB1-PcrV) were pooled and incubated overnight with 250 L of 0.04 mM 
recombinant TEV protease at room temperature in buffer (20 mM NaCl, 20 mM Tris-HCl pH 8.0, 1 mM 
DTT, 0.5 mM EDTA).  The digested protein was dialyzed in binding buffer and passed through a second 
round of Ni2+-affinity purification.  LcrV (or PcrV) eluted in the flow through and wash fractions, while 
the His6-GB1 tag was retained in the column.  Both LcrV and PcrV retained a 3-residue N-terminal 
cloning artifact ‘GHM’.  The purified proteins were either dialyzed in 1.05X phosphate-buffered saline 
(PBS, pH 7.4 for SPR screening) or NMR buffer (20 mM NaCl, 10 mM NaPO4 pH 6.8).  The proteins 
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were concentrated using Amicon Ultra 10K centrifugal filters (Millipore) and concentrations were 
measured by A280.  
 
3.3.2.  Surface plasmon resonance (SPR) screening   
 
A library of 288 compounds (Zenobia fragment library 2, San Diego, CA, 
http://www.zenobiafragments.com) was obtained as dry films in three 96-well microplates.  Compounds 
were dissolved in 100% DMSO to produce a stock concentration of 100 mM.  The working solution was 
made by diluting compounds to a final concentration of 1 mM in 5% DMSO and 1.05X PBS (running 
buffer).   
 
 SPR data were acquired at 25°C using a BIACORE 3000 instrument (GE Healthcare).  The 
screening was carried out as previously with minor modifications (22).  Briefly, the target proteins LcrV 
and PcrV were immobilized onto a CM5 sensor chip using standard amine-coupling chemistry.  
Activation, coupling and blocking steps were performed for 7 minutes each resulting in final 7,906 
response units (RU) for LcrV and 6,673 RU for PcrV.  BIACORE 3000 allowed the automated injection 
of compounds from 96-well plates.  Compounds were injected into the flow cells and allowed to associate 
for 30 sec and dissociate for 60 sec.  Running buffer was injected between each compound run to monitor 
carryover effects. 
  
3.3.3.  NMR spectroscopy   
 
Saturation transfer difference (STD) NMR data were acquired at 30C using a Bruker Avance III 
600 MHz spectrometer equipped with a TXI-RT probe and processed using Topspin.  Samples were 
prepared by mixing protein and compound at a molar ratio of 1:100 (40 M protein + 4000 M 
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compound).  One-dimensional 1H STD spectra were acquired by saturating the protein using 50 ms 
shaped saturation pulse over a period of 2 sec with center of the on-resonance pulse varied from -0.9 to -
1.1 ppm for optimal STD signal, while the off-resonance pulse was maintained at 40 ppm.  1D 1H NMR 
of the structures was predicted using ChemDraw.  
 
 Two-dimensional 1H-15N TROSY, 1H-13C ILV methyl HSQC, and three-dimensional HNCA, 
HNCACB, CBCA(CO)NH, and HMQC-NOESY-HMQC data on LcrV were acquired using a Bruker 
Avance 800 MHz spectrometer equipped with a TCI cryoprobe.  Two-dimensional 1H-15N TROSY and 
1H-13C ILV methyl HSQC spectra on PcrV were collected using Bruker Avance III 600 MHz 
spectrometer.  The data were acquired at 30C, processed using NMRPipe (23) and analyzed using 
NMRView (24).  For backbone assignments, sample containing ~0.7 mM perdeuterated 15N/13C-labeled 
LcrV in 500 L of NMR buffer with 10% D2O was prepared.  The ILV methyl resonances of LcrV were 
assigned following the published protocol (25,26).  A 500 L sample containing ~0.35 mM perdeuterated 
15N/ILV-labeled LcrV in NMR buffer was lyophilized and re-suspended in 100% D2O.  Three-
dimensional data were collected using a mixing time of 300 ms and a relaxation delay of 2 sec.  To assist 
in the ILV assignment, twenty-four isoleucine to leucine point mutants in LcrV, and four isoleucine to 
leucine and leucine to alanine mutants in PcrV were made using site-directed mutagenesis (Stratagene).  
The mutants were expressed and purified as above and 2D 1H-13C HSQC spectra were acquired and 
compared with the wild type to assign the missing resonance.  For NMR titrations, the compounds were 
dissolved in 100% d6-DMSO (CIL).  ILV and 15N chemical shift mapping were performed by acquiring 
2D 1H-13C HSQC and 1H-15N TROSY spectra on 0.29 mM 15N/ILV-labeled LcrV (or 0.31 mM 15N/ILV-
labeled PcrV) titrated with increasing concentrations of the compound.  All the titration samples 
contained 2% (v/v) d6-DMSO and 10% D2O.  The weighted chemical shift deviations (CSD) were 
calculated using: 0.5[(H)2 + (C/2)2]1/2 for ILV titrations and 0.5[(H)2 + (N/5)2]1/2 for 15N titrations 
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(27).  The binding dissociation constants were estimated by non-linear curve fitting of CSDs vs. 
compound concentration plots for representative residues using GraphPad Prism 5.0. 
 
 
3.4.  Results 
 
3.4.1.  SPR-based fragment screening  
  
The expression and purification of LcrV (residues 28-322, C273S) and PcrV (residues 25-294) 
generated millimolar amounts of purified proteins.  High stability and solubility of these proteins 
facilitated SPR screening followed by hit validation and characterization by NMR.  SPR screening of 288 
compounds from a structurally diverse fragment library (Zenobia fragment library 2) identified novel 
small molecules binding to LcrV and PcrV.  Interestingly, 3-(1H-pyrrol-1-yl)benzo[b]thiophene-2-
carboxylic acid (PBTCA) showed binding to both LcrV and the homolog, PcrV (Figure 3-1A, 3-1D).  
Additionally, screening results also displayed the binding of 5-hydroxyindole and 4-(4-
methylpiperazino)aniline to LcrV (Figure 3-1B, 3-1C); and 3-amino-7-bromoquinoline to PcrV (Figure 
3-1E). 
 
Analysis of structure-activity relationship (SAR) of the hit compounds (1, 4, 8, and 11, Figure 3-
2) with non-binder analogs within the library enabled the determination of chemical groups important for 
the binding.  The pyrrole moiety of PBTCA (1, Figure 3-2) was required for binding LcrV and PcrV as 
its removal (2, Figure 3-2) abolished the interaction with both the proteins (Figure 3-3A, 3-3B).  
Likewise, the thiophene carboxylic acid alone was incapable in binding LcrV and PcrV (3).  The hydroxyl 
group of 5-hydroxyindole (4) was important to bind LcrV since its removal (5) or modification with an 
aza or a cyano group (6, 7) interfered with the binding.  Regarding the binding of the piperazinoaniline 
scaffold to LcrV (8), the 4-methyl group of piperazine was necessary as its replacement with a 
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morpholine ring (9) or removal (10) resulted in loss of binding.  For the quinoline scaffold binding to 
PcrV (11), substituting bromine at position 7 with fluorine (12) abrogated the interaction (Figure 3-3C).  
Similarly, removal of the amine and the bromide groups and introduction of a carboxylic acid (13) also 
disrupted the binding.  Our initial SAR studies suggest that specific molecular interactions between the 




Figure 3-1. SPR screening of LcrV and PcrV.  SPR sensorgrams displaying the binding of (A) 3-(1H-
pyrrol-1-yl)benzo[b]thiophene-2-carboxylic acid (PBTCA), (B) 5-hydroxyindole, and (C) 4-(4-
methylpiperazino)aniline to LcrV, (D) PBTCA, and (E) 3-amino-7-bromoquinoline to PcrV. 





Figure 3-2.  Structures of the fragment hits and their analogs.  SPR screening showed the binding of 
PBTCA (1) to both LcrV and PcrV, 5-hydroxyindole (4) and 4-(4-methylpiperazino)aniline (8) to LcrV, 
and 3-amino-7-bromoquinoline (11) to PcrV.  The non-binding analogs highlight the important chemical 
groups required for binding to LcrV or PcrV.  The structures were made using ChemDraw. 
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3.4.2.  Validation of fragment hits using STD NMR   
 
Ligand-observed saturation transfer difference NMR (STD NMR) is a powerful tool to quickly 
validate the fragments identified as hits in the initial screening and to recognize ligand moieties important 
for the binding.  Results of STD NMR confirmed the direct interaction of PBTCA, 5-hydroxyindole, and 
4-(4-methylpiperazino)aniline to LcrV (Figure 3-4A, 3-4B, 3-4C), and PBTCA and 3-amino-7-bromo-
quinoline to PcrV (Figure 3-4D, 3-4E).  As expected, the off-resonance reference spectra showed NMR 
signals from both compound and protein (Figure 3-4, top panel).  Importantly, strong STD signals were 
readily observable for all the five hits (Figure 3-4, bottom panel).  Since most of the NMR signals 
corresponding to the compound remained above noise level in all the resultant STD spectra (Figure 3-4), 
this suggests that the entire molecule is binding or is in close proximity of the target protein. 
 
3.4.3.  NMR assignments of LcrV   
 
Chemical shift assignment is a critical first step in NMR-based protein interaction studies.  LcrV 
(with 295 residues) is a large protein, making the NMR backbone amide assignment challenging.  Side 
chain methyl ILV (Isoleucine, Leucine, and Valine) groups with high sensitivity and sharp NMR 
resonances offer useful probes for spectroscopic studies of high molecular weight proteins (28).  The 25 
isoleucine, 31 leucine, and 14 valine residues of LcrV are distributed among the 3 distinct parts of the 
protein: the N-terminal globular region, the central coiled-coil, and the distal region, and provide 
coverage of the entire protein.  The 2D 1H-13C HSQC spectrum of ILV labeled LcrV showed 109 of the 
expected 115 peaks (1 peak for each Ile, and 2 peaks for each Leu and Val residue, (Figure 3-5).  Using a 
combination of site-directed mutagenesis (Ile to Leu mutations, Figure 3-6) and through space 1H-1H 
nuclear Overhauser effects (NOEs) obtained from 3D HMQC-NOESY (25) and analyzed using the 
crystal structure of LcrV (11) (Figure 3-7), near complete methyl ILV assignments were obtained 
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(Figure 3-5, 67 assigned of the total 70 ILV residues; V63, L75, and L85 remain unassigned due to 
missing or overlapping peaks).  Although challenging, 53 of the total 295 backbone amide peaks were 
also assigned using 3D HNCA, 3D HNCACB and 3D CBCA(CO)NH (Figure 3-8).  These are currently 
the only available methyl ILV and backbone amide assignments for the entire LcrV family of T3SS tip 




Figure 3-3.  SPR sensorgrams of representative non-binding analogs of the hit fragments from 
LcrV and PcrV.  Benzo[b]thiophene-2-carboxylic acid, an analog of PBTCA (1, Figure 3-2) shows no 
binding to (A) LcrV, or (B) PcrV.  (C) 3-amino-7-fluoroquinoline, an analog of 3-amino-7-





Figure 3-4.  STD NMR of the fragment hits.  (A) PBTCA, (B) 5-hydroxyindole, and (C) 4-(4-
methylpiperazino)aniline with LcrV, (D) PBTCA, and (E) 3-amino-7-bromoquinoline with PcrV.   










Figure 3-6.  Site-directed mutagenesis approach used in assigning isoleucine 13Cδ1 methyl peaks of 
LcrV.  (A-D) 2D 1H-13C HSQC spectra of selected isoleucine to leucine mutants of LcrV (red) overlaid 
with the wild type reference spectra (black).  The single missing peak corresponding to the mutated 





Figure 3-7.  The nuclear Overhauser effect (NOE) used in the assignment of ILV methyl resonances 
of LcrV.  (A) Representative strips from a 3D 1H-13C-13C HMQC-NOESY-HMQC dataset of 
perdeuterated ILV labeled LcrV.  Asterisks mark the diagonal peak and NOEs with other residues are 
shown with blue lines.  (B) Crystal structure of LcrV (PDB ID: 4JBU) with the ILV methyl groups shown 
in spheres (Ile C1, red; Leu C, magenta & pink; Val C, blue & light blue).  An expansion of a region 






Figure 3-8.  Assigned 2D 1H-15N TROSY spectrum of LcrV.  Residues indicated with asterisk appeared 
at a lower contour level.  Partially assigned by Dr. Narsimulu Kongari. 
 
3.4.4.  NMR titrations of ILV and 15N-labeled LcrV with PBTCA   
 
To determine the binding site of PBTCA on LcrV, ILV and 15N-labeled LcrV was titrated with 
increasing concentrations of PBTCA at molar ratios of 1:0, 1:4, 1:8, and 1:14.  Simultaneous ILV and 15N 
labeling of LcrV enabled titration to be monitored with two different probes.  First, 2D 1H-13C HSQC 
spectra were acquired for various titration points to investigate the effect of PBTCA on the ILV methyl 
resonances of LcrV (Figure 3-9A), and second, 2D 1H-15N TROSY spectra were acquired to query the 
effect of interaction on 15N backbone amides of LcrV (Figure 3-9B).  The stepwise addition of PBTCA 
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resulted in significant chemical shift perturbations of specific LcrV resonances.  Both the ILV and amide-
based titrations showed concentration dependent changes in the peak positions for the affected LcrV 
residues (e.g. I64, I174, L240, L320, S47, G87, G88, and Q112), indicating interaction to be in fast 
exchange NMR time scale (Figure 3-9C, 3-9D).  
 
To map the LcrV/PBTCA interaction interface, we calculated the weighted chemical shift 
deviation (CSD) for each assigned non-overlapped ILV (Figure 3-10A) and amide (Figure 3-10B) peak 
of LcrV.  Residues that displayed significant CSD (average plus a standard deviation) varied from 
hydrophobic (L35, I64, L79, L126, I174, I184, and L240) to polar uncharged (S47, Y77, T183, and T272) 
residues.  Results of the ILV titrations complemented backbone amide titrations and together indicated 
that the affected residues map largely on two surfaces on LcrV: bottom of the N-terminal globular domain 
formed by residues L35, I64, Y77, L79, and L126; and top of the central coiled-coil involving residues 
I174, T183, I184, L240, and T272 (Figure 3-10C).  Although CSDs of residues at the top of the central 
coiled-coil did not reach saturation by our final titration point, based on the CSDs of residues located in 
the N-terminal globular region (S30, L126, and T127), the binding dissociation constant of 7 ± 1 mM 
could be estimated for the LcrV/PBTCA interaction (Figure 3-10D).  Accordingly, it can be speculated 
that PBTCA primarily binds near the bottom of the N-terminal globular domain, whereas the top of the 
coiled-coil probably presents a weaker secondary binding site for the LcrV/PBTCA interaction. 
 
3.4.5.  NMR titrations of LcrV with 5-hydroxyindole and 4-(4-methylpiperazino)aniline   
 
Besides PBTCA, LcrV also displayed binding to two other scaffolds, 5-hydroxyindole and 4-(4-




Figure 3-9.  ILV and 15N NMR titrations of LcrV with PBTCA.  Overlay of four (A) 2D 1H-13C 
HSQC spectra, and (B) 2D 1H-15N TROSY spectra of ILV and 15N-labeled LcrV titrated with increasing 
molar ratios of PBTCA.  Expanded sections of selected LcrV residues affected by the interaction with 





Figure 3-10.  Analysis of the interaction of LcrV with PBTCA.  Plots of weighted chemical shift 
deviation (CSD) from (A) ILV and (B) 15N titrations of LcrV with PBTCA.  Gray and red lines 
correspond to the mean and one standard deviation (1) from the mean, respectively.  Residues with no 
deviation (zero CSD value) are shown with asterisk.  (C) LcrV residues strongly affected by the binding 
of PBTCA shown in red.  (D) Plot of CSD vs. concentration of PBTCA for selected residues. 
 
 NMR titrations of LcrV with 5-hydroxyindole at protein to compound ratios of 1:0, 1:25, 1:50, 
and 1:92 resulted in concentration dependent deviation in the peak positions of specific LcrV residues as 
shown by 13C HSQC (Figure 3-11A and Figure 3-12A) and 15N TROSY (Figure 3-11B and Figure 3-
12B), suggesting interaction in fast exchange NMR time scale.  Analysis of the CSDs for ILV (Figure 3-
12C) and amide (Figure 3-12D) titrations identified that majority of the affected residues reside in the N-
terminal globular domain of LcrV and few lie near the middle of the coiled-coil (Figure 3-12E).  Except 
for some distant residues, such as, V140, L157, and I294, residues showing significant CSDs mainly 
clustered around the bottom of the N-terminal globular region, the region identified earlier important for 
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PBTCA binding (Figure 3-10C).  Based on nonlinear regression fits of CSDs vs 5-hydroxyindole 
concentration for some representative affected residues (L38, G87, I309, and Q317), the dissociation 
constant of 29 ± 5 mM was determined for the binding of 5-hydroxyindole to LcrV (Figure 3-11C).  
 
Similar to the ILV and amide titrations of LcrV with PBTCA (Figure 3-9) and 5-hydroxyindole 
(Figure 3-11), addition of 4-(4-methylpiperazino)aniline at molar ratios of 1:0, 1:12, 1:25, and 1:50 
induced distinct chemical shift deviations of specific LcrV resonances (Figure 3-13A, 3-13B).  
Representative set of residues affected by 4-(4-methylpiperazino)aniline from the ILV (L38, I46, V101, 
and L178) and 15N (S47, W113, G147, and G200) titrations exhibited peaks in fast exchange NMR time 
scale (Figure 3-14A, 3-14B).  Plots of the CSDs (Figure 3-13C, 3-13D) identified that the LcrV residues 
strongly perturbed by 4-(4-methylpiperazino)aniline are primarily confined towards the bottom of the N-
terminal globular domain.  The binding dissociation constant of 13 ± 1 mM was estimated based on the 
CSDs of some significantly affected residues (I46, V138, G147, and T272, Figure 3-13E).  Together, 
based on the interaction studies of LcrV with PBTCA, 5-hydroxyindole and 4-(4-
methylpiperazino)aniline, region near the bottom of the N-terminal globular domain of LcrV is expected 
to be the “hotspot” for small molecule fragment binding. 
 
3.4.6.  PcrV binds to PBTCA and 3-amino-7-bromoquinoline   
 
In addition to LcrV, we also screened for fragments binding to PcrV, the LcrV homolog in P. 
aeruginosa.  Interestingly, PBTCA, the fragment identified earlier as binding to LcrV, also showed 
binding to PcrV (Figure 3-1D, 3-4D).  Apart from PBTCA, SPR and STD NMR also displayed the 
binding of 3-amino-7-bromoquinoline to PcrV (Figure 3-1E, 3-4E).  Our efforts to assign the methyl ILV 
resonances of PcrV utilizing the previously described ‘NOE’ based assignment approach have so far been 
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unsuccessful due to lack of high-resolution structure of PcrV.  However, using site-directed mutagenesis, 




Figure 3-11.  ILV and 15N NMR titrations of LcrV with 5-hydroxyindole.  Overlay of four (A) 2D 1H-
13C HSQC spectra, and (B) 2D 1H-15N TROSY spectra of ILV and 15N-labeled LcrV titrated with 
increasing molar ratios of 5-hydroxyindole.  Expanded views of boxed residues are shown in Figure 3-12.  








Figure 3-12.  Analysis of the interaction of LcrV with 5-hydroxyindole.  Representative LcrV residues 
affected by interaction with 5-hydroxyindole in (A) ILV and (B) 15N NMR titrations.  Plots of CSD from 
(C) ILV and (D) 15N titrations of LcrV with 5-hydroxyindole.  Gray and red lines correspond to the mean 
and one standard deviation (1) from the mean, respectively.  Residues with no deviation (zero CSD 
value) are shown with asterisk.  (E) LcrV residues strongly affected by the binding of 5-hydroxyindole 






Figure 3-13.  ILV and 15N NMR titrations of LcrV with 4-(4-methylpiperazino)aniline.  Overlay of 
four (A) 2D 1H-13C HSQC spectra and (B) 2D 1H-15N TROSY spectra of ILV and 15N-labeled LcrV 
titrated with increasing mole ratio of 4-(4-methylpiperazino)aniline.  Expanded views of boxed residues 
are shown in Figure 8 of the main text.  The vertical signals at ~6.8 ppm in (B) are from compound.  Plots 
of CSD from (C) ILV and (D) 15N titrations of LcrV with 4-(4-methylpiperazino)aniline.  Gray and red 
lines correspond to the mean and one standard deviation (1) from the mean, respectively.  Residues with 
no deviation (zero CSD value) are shown with asterisk.  (E) Plot of CSD vs. concentration of 4-(4-





Figure 3-14.  NMR titration results of LcrV with 4-(4-methylpiperazino)aniline.  Expanded sections 
of representative LcrV residues affected by the interaction of 4-(4-methylpiperazino)aniline in (A) ILV 
and (B) 15N NMR titrations.  (C) LcrV residues affected by the binding of 4-(4-methylpiperazino)aniline 





Figure 3-15.  Site-directed mutagenesis approach used in assigning ILV methyl peaks of PcrV.  (A-
H) 2D 1H-13C HSQC spectra of selected isoleucine to alanine mutants of PcrV (red) overlaid with the 
wild type reference spectra (black).  The missing peak corresponding to the mutated residue is labeled.  
Occasionally, ILV residues in close proximity of the mutated residue showed chemical shift perturbation.  
Asterisk indicates a folded leucine peak of PcrV. 
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Stepwise titration of ILV and 15N labeled PcrV with PBTCA at 1:0, 1:4, and 1:8 molar ratios and 
monitored by 13C HSQC (Figure 3-16A) and 15N TROSY (Figure 3-17A) showed distinct chemical shift 
perturbations of specific PcrV resonances in a concentration dependent manner.  In both ILV and amide 
titrations, along with progressive changes in the peak positions for some affected PcrV residues (boxed 
peaks depicting fast exchange phenomenon), other PcrV residues affected upon PBTCA binding showed 
decrease in their peak intensities (peaks shown by arrows indicative of intermediate exchange NMR time 
scale, Figure 3-16A, Figure 3-17A).  Likewise, NMR titrations with 3-amino-7-bromoquinoline at 
protein to compound ratios of 1:0, 1:2, and 1:4 showed both the deviations in peak positions and 
reduction in the peak intensities for the affected residues (Figure 3-16B and Figure 3-17B).  Even 
though most of the NMR assignments for PcrV are currently not available, it is evident that the 
resonances affected by PBTCA and 3-amino-7-bromoquinoline are largely same in both ILV (Figure 3-
16A compared with 3-16B) and 15N amide titrations (Figure 3-17A compared with 3-17B), suggesting 
that both fragments recognize a similar surface on PcrV.  Using the assigned ILV resonances, L105, L121, 
I280, and I290 were identified as strongly affected residues in both PBTCA and 3-amino-7-
bromoquinoline titrations (Figure 3-16A, 3-16B).  Mapping the affected residues onto the I-TASSER 
model of PcrV (13) highlight region near the N-terminal domain of PcrV (Figure 3-16C).  Our results 
suggest that similar to the fragment binding pocket of LcrV, region near the N-terminal globular domain 
of PcrV likely provides the interaction site for small molecule binding. 
 
 
3.5.  Discussion 
 
The T3SS V-tip proteins, LcrV and PcrV are crucial virulence factors of Y. pestis and P. 
aeruginosa, respectively (9,14).  Since these proteins are exposed on the bacterial surface and 
indispensable for the proper assembly and functioning of the T3SS, they represent an attractive target for 
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the development of anti-virulence drugs (5,29-32).  Here, we identified and characterized the binding of 
three novel small molecules, PBTCA, 5-hydroxyindole, and 4-(4-methylpiperazino)aniline to LcrV, and 
two molecules, PBTCA and 3-amino-7-bromoquinoline to PcrV.  The fragments identified in this work 
represent the first small molecules shown to bind to LcrV and PcrV (Figure 3-1 and Figure 3-2) and 




Figure 3-16.  ILV titrations of PcrV with PBTCA and 3-amino-7-bromoquinoline.  Overlay of three 
2D 1H-13C HSQC spectra of ILV-labeled PcrV titrated with increasing mole ratios of (A) PBTCA and (B) 
3-amino-7-bromoquinoline.  (C) I-TASSER model of PcrV with residues affected in titrations with 





Figure 3-17.  15N NMR titrations of PcrV with PBTCA and 3-amino-7-bromoquinoline.  Overlay of 
three 2D 1H-15N TROSY spectra of 15N-labeled PcrV titrated with increasing molar ratios of (A) PBTCA 
and (B) 3-amino-7-bromoquinoline.  Residues displaying changes in peak positions are indicated with a 
box and residues with peak intensity reduction are marked with an arrow.   
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NMR spectroscopy is unparalleled in its ability to detect molecular interactions and characterize 
ligand binding at the atomic level over a wide range of affinities, and thus, valued highly in the drug 
discovery research (33-35).  However, NMR characterization of molecular interactions of T3SS V-tip 
proteins has not yet been feasible largely due to lack of resonance assignments for this protein family.  
NMR assignment of backbone amides of the V-proteins is particularly challenging because of their large 
molecular weight (LcrV, 34 kDa and PcrV, 31 kDa), poor NMR data quality with significant signal 
overlap and peak broadening, and tendency to aggregate at high protein concentrations (PcrV at 
concentrations above 0.4 mM shows substantial peak broadening compared to a lower concentration 
sample).  Perdeuteration of LcrV in combination with TROSY-based NMR experiments (36) resulted in 
sensitivity gains and resolution enhancement, allowing partial backbone amide assignment of LcrV 
(Figure 3-8).  However, increasing the total deuteration by replacement of non-deuterated D-glucose (U-
13C6) as the carbon source to fully deuterated D-glucose (U-13C6; 1,2,3,4,5,6,6-d7) did not further simplify 
spectral analysis to facilitate additional backbone amide assignments.  Since methyl groups occur 
frequently in the hydrophobic cores of the protein and many protein-protein and protein-small molecules 
interactions often involve hydrophobic interfaces (28), we used sensitive ILV side chain methyl groups as 
alternative probes in the NMR studies of the V-proteins.  Similar to the amide moieties, perturbations of 
ILV methyl groups can be used to determine ligand binding and map the interaction surfaces (28,37).  
Correlation of methyl 1H-1H NOEs with the distance information from our previously reported crystal 
structure of LcrV (11) enabled near complete methyl ILV assignments of LcrV (Figure 3-5), which were 
successfully utilized here to characterize the interaction of LcrV with small molecules.  The assignments 
provided herein are the only available NMR assignments for LcrV family of tip proteins and would assist 
in further molecular interaction studies of LcrV.  
 
Analysis of the interaction of LcrV with PBTCA (Figure 3-10), 5-hydroxyindole (Figure 3-11), 
and 4-(4-methylpiperazino)aniline (Figure 3-14) reveal that all three hit fragments predominantly 
perturbed a similar surface on LcrV, bottom of the N-terminal globular domain.  In addition to the N-
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terminal domain, PBTCA also affected residues near top of the central coiled-coil of LcrV (Figure 3-10).  
Since chemical shift perturbations can occur because of number of direct and indirect structural and 
dynamic effects, the other affected surface of LcrV could be a result of conformational changes induced 
upon the binding of PBTCA in the N-terminal globular domain or represent a secondary binding site for 
PBTCA.  Even though with the limited number of assignments for PcrV, the observation that PBTCA and 
3-amino-7-bromoquinoline affected residues near the N-terminal domain of PcrV highlight the 
importance of this region in small molecule binding (Figure 3-16).  Together, the data implies that 
surface near the bottom of the N-terminal domain of V-proteins represent a “hotspot” for binding small 
molecule fragments.  Interestingly, the N-terminal globular domain of the V-proteins forms the basal 
structure of the needle tip complex and provides a crucial surface for the interaction with the YscF needle 
protein (9,31).  Furthermore, previous biophysical studies have shown the important role of the N-
terminal domain in regulating the overall stability of the V-proteins (38).  Additionally, the N-terminal 
domain has also been recognized to determine the efficiency of pore formation by acting as an assembly 
platform for the functional insertion of translocators into the host cell membrane (39).  Given these 
significant roles of the N-terminal domain of V-proteins, our fragment binding site represents a 
biologically relevant hotspot that could be exploited to interfere with the assembly of the T3SS.  
 
NMR titrations of small molecules with their cognate protein indicated interactions primarily in 
fast exchange regime with dissociation constants in the mM range (Figure 3-9, Figure 3-11, Figure 3-14, 
and Figure 3-16).  Such weak binding affinity by the compounds was expected given these are only 
small fragments (MW ~ 200 Da) that need to be optimized to generate a lead compound with higher 
affinity (34,35).  Fragment follow-up strategies such as, linking, merging, and/or chemical modification 
should help in the development of more potent compounds (34).  Interestingly, the phenylene and the 
methyl piperazine moiety from our fragment hit 4-(4-methylpiperazino)aniline (8, Figure 3-2), upon 
combination with the quinoline moiety from our hit 3-amino-7-bromoquinoline (11, Figure 3-2) would 
provide a scaffold chemically related to INP1750 [5-nitro-7-((4-phenylpiperazine-1-yl-)methyl)quinolin-
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8-ol], a compound that has been previously identified as a potent inhibitor of T3SS in Y. 
pseudotuberculosis and C. trachomatis (19).  Although the specific molecular target of INP1750 in T3SS 
is currently unknown, presence of the phenyl + piperazine methyl + quinoline based scaffold could be 
associated with the inhibition of the tip protein of T3SS.  It further demonstrates that the scaffolds 
identified in this work are promising starting structures that could be used in the development of specific 
inhibitors of the T3SS.  Recently, 5-hydroxyindole (4, Figure 3-2) was shown to bind to SipD, the LcrV 
homolog in the Salmonella T3SS (22).  Since most of the T3SS proteins are conserved across multiple 
bacterial pathogens, it is not surprising that the identified hits might interact with homologs of the target 
protein.  In fact, T3SS inhibitors, such as acylhydrazides and thiazolidinones are effective against a wide 
range of Gram-negative bacterial pathogens, indicating a conserved T3SS protein as their likely target 
(15,40). 
 
In summary, we have identified the first class of small molecules that bind to LcrV (PBTCA, 5-
hydroxyindole, and 4-(4-methylpiperazino)aniline) and PcrV (PBTCA and 3-amino-7-bromoquinoline).  
These scaffolds provide a good starting point for fragment elaboration to enable the development of 
potent lead compounds targeting the T3SS. 
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Chapter 4: Concluding Remarks and Future Directions for T3SS Project
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The T3SS is critical in the pathogenesis of many Gram-negative bacteria that infect humans (1-3).  
The structural component of the T3SS is a needle apparatus that function as a syringe to inject effector 
proteins from bacterial cytoplasm directly into the target eukaryotic cells.  The T3SS needle apparatus is 
assembled from over 20 different proteins and is composed of a base that spans the bacterial membranes, 
an extracellular needle, a tip protein complex, and a translocon that punctures a hole in the host cell 
membrane (4).  Since the visualization of this sophisticated bacterial nanomachine almost two decades 
ago, remarkable progress has been made towards determining high-resolution structures of various 
components of the needle apparatus (1,3-8).  However, the assembly mechanism, specifically, the atomic 
details of protein-protein interactions involved in the assembly of the needle apparatus remain poorly 
understood.  High-resolution models of the base and the needle are now available, but, much less is 
known regarding the tip-translocon protein-protein interactions (7,8).  Therefore, the first aim of the T3SS 
research described in this dissertation was to fill this gap by gaining insights into the interactions of the 
Shigella tip protein IpaD and the major translocon protein IpaB.  Furthermore, because the T3SS is 
crucial in virulence, surface-exposed, and highly conserved in structure and function among different 
pathogenic bacteria, disrupting the needle apparatus of T3SS is an exciting target for the development of 
novel anti-infectives (2,9,10).  Thus, the second aim of the T3SS research presented in this dissertation 
was directed at identifying and characterizing small molecule binders of the T3SS proteins that could be 
used as potential starting structures in the drug design of inhibitors of T3SS. 
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4.1.  IpaD-IpaB tip-translocon protein-protein interaction 
 
4.1.1.  Key findings and significance 
 
The translocon is assembled from the major and the minor translocon proteins.  IpaB, the major 
translocon protein of Shigella, is an integral membrane protein that contains an N-terminal cytosolic 
ectodomain, a central conserved hydrophobic region with two transmembrane helices, and a C-terminal 
amphipathic region (11).  The transmembrane and the C-terminal amphipathic regions have been shown 
to be important for the membrane insertion of the major translocon proteins (11,12).  Prior to this work, 
the role of the cytosolic N-terminal ectodomain in the assembly of the translocon was unclear.  Based on 
the topology of IpaB, we hypothesized that the soluble N-terminal ectodomain could be responsible for 
the attachment of the translocon to the tip complex.  NMR methods were used to study this protein-
protein interaction, as summarized in Chapter 2.  NMR chemical shift mapping revealed a direct 
interaction between the tip protein IpaD and the N-terminal ectodomain of the major translocon protein 
IpaB.  Changes in the NMR peaks brought about by IpaD-IpaB complex formation were primarily in the 
intermediate exchange regime on NMR timescale, indicating a weak ‘M’ range binding affinity.  
Therefore, I used sensitive PRE methods utilizing spin labels to gain further insights into this weak 
interaction (13,14).  Results of NMR chemical shift perturbations complemented PRE studies and they 
together indicated that the distal region of the tip protein IpaD (the mixed - domain) is the primary 
binding site for the N-terminal ectodomain of IpaB (Chapter 2).   
 
Such detailed characterization of the surfaces involved in the tip-translocon protein-protein 
interactions on a per-residue resolution level was unavailable for any type III secretion system.  This work 
has expanded our current knowledge about the assembly of the needle apparatus of the T3SS.  Our results 
have further provided structural basis for understanding previous mutational studies that showed deletion 
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of the distal region of IpaD abolishes the localization of IpaB on the needle tip (15).  Additionally, our 
results are in agreement with the recent model of the Shigella tip complex derived by electron microscopy 
that displays the distal region of IpaD points outside in the assembled tip, and, thus available to mediate 
tip-translocon protein-protein interactions (16).  However, in contrast to the previous fluorescence 
polarization studies indicating essential role of bile salt deoxycholate (DOC) in IpaD-IpaB binding (17), 
our IpaD-IpaB interaction studies in the absence or presence of DOC showed no major alteration in the 
protein binding affinity or the interaction surfaces. 
 
4.1.2.  Future directions to understand the assembly of the needle apparatus 
 
The tip-translocon interaction studies presented in this dissertation combined with the previous 
data on the needle-tip interaction (18,19) put forward a needle-tip-translocon interaction model centered 
on the tip protein IpaD, where the proximal end of the IpaD (bottom of the coiled-coil) binds with the 
needle protein, and the distal domain of IpaD interacts with the cytosolic ectodomain of IpaB (Chapter 2).  
However, to gain better appreciation of the intricate assembly mechanism of the needle apparatus and 
understand the role of the minor translocon protein in assembling a functional translocon, further testing 
is mandatory.   
 
Firstly, although the binding surfaces on IpaD that are involved in the interaction with IpaB have 
been well characterized, the reverse is not explicitly known.  PRE spin labeling on IpaB suggested region 
near the top of the trimeric coiled-coil of the N-terminal ectodomain of IpaB as important for the binding 
of IpaD.  Future experiments following reverse labeling, i.e., isotopically labeled IpaB titrated with 
unlabeled or spin-labeled IpaD would help in clear elucidation of the interaction surfaces of IpaD on the 
N-terminal domain of IpaB.  Towards this direction, given the IpaD-IpaB interaction is weak, we used 
sensitive side chain methyl isoleucine labeling (20,21) and tested various N-terminal constructs of IpaB to 
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find an ideal construct for NMR studies.  The longer N-terminal constructs, IpaB residues 9-226 and IpaB 
residues 76-308, containing flexible domains showed poor NMR data quality (Figure 4-1A, B).  In 
contrast, IpaB residues 74-224, a protease-resistant fragment lacking disordered regions, gave an ideal 
NMR spectrum with all the 14 expected Ile resonances (Figure 4-1C).  These findings suggest IpaB 
residues 74-224 is an ideal construct that could be utilized for reverse NMR binding studies to 
characterize the full spectrum of IpaD and N-terminal ectodomain IpaB interactions. 
 
Secondly, a major concern of using the N-terminal ectodomain of the major translocon protein 
IpaB in the tip interaction studies is that this fragment, although essential for IpaD binding, may not 
contain the entire surface of IpaB required for the IpaD binding.  It is important to test how the full-length 
IpaB interacts with IpaD and vice-versa to understand the translocon assembly.  Additionally, both major 
and minor translocon proteins are required to assemble a functional translocon (22,23).  To gain insights 
into the interactions of an assembled translocon, it would be of immense importance to characterize the 
protein-protein interactions of the minor translocon protein (IpaC in Shigella) in addition to the major 
translocon protein IpaB.  This is challenging since the translocon proteins, IpaB and IpaC, are integral 
membrane proteins (4).  However, full-length translocon proteins can be expressed with their cognate 
chaperone proteins (IpgC in Shigella) to obtain a soluble complex (24).  Studies have shown that a very 
small region (the extreme N-terminus) of the translocon protein is actually needed to mediate interactions 
with the chaperone (25,26), justifying the use of chaperone-bound soluble translocon complexes in the 
structural characterization and protein-protein interaction studies.  Towards this goal, I subcloned, co-
expressed, and co-purified full-length major translocon protein IpaB with the chaperone IpgC, and full-
length minor translocon protein IpaC with IpgC.  Because of the poor expression of the Shigella proteins, 
I also subcloned, expressed, and purified Yersinia full-length major and minor translocon proteins, YopB 
and YopD, respectively, with the chaperone LcrH.  Unfortunately, the Yersinia proteins were not stable 
enough and degraded upon purification.  Preliminary structural and biophysical characterization was 




Figure 4-1.  Two-dimensional 1H-13C HSQC spectra of side chain methyl Ile-labeled IpaB N-
terminal constructs.  (A) IpaB residues 9-226, (B) IpaB residues 76-308, and (C) IpaB residues 74-224. 
 
NMR spectroscopy.  However, the full-length translocon-chaperone complexes, IpaB-IpgC and IpaC-
IpgC, gave poor quality NMR data (Figure 4-2).  The translocon proteins can be separated from the 
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translocon-chaperone complexes using detergents, urea or pH treatment (27,28).  Upon pH change, most 
of the IpaC degraded, but IpaB could be stably dissociated from IpaB-IpgC complex and could be 
maintained in OPOE/LDAO detergents.  Although 13C-methyl isoleucine labeled full-length IpaB showed 
fewer peaks than expected, the data look promising with sharp and dispersed peaks (Figure 4-2C).  
Future experimental optimization, better NMR labeling schemes (side chain methionine labeling), 
deuteration, different detergent combinations, use of nanodiscs, and other techniques, such as, EPR and 





Figure 4-2.  NMR spectroscopy on full-length translocon proteins from Shigella flexneri T3SS.  (A) 
2D 1H-15N TROSY spectrum of IpaB-IpgC complex, 2D 1H-13C HSQC spectra of Ile-labeled (B) IpaB-
IpgC complex, (C) free IpaB in 0.03% LDAO, and (D) IpaC-IpgC complex. 
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4.2.  Small-molecule binders of the T3SS tip proteins LcrV and PcrV  
 
4.2.1.  Key findings, significance, and future directions 
 
Antibiotic resistance in Gram-negative bacteria is a looming public health threat that requires new 
targets for the development of novel anti-bacterials (29).  Since the T3SS is essential for virulence and 
colonization within a host, exposed on the bacterial surface, and present only in the pathogens, disrupting 
the assembly of the T3SS is an attractive target for developing novel anti-virulence drugs (2,9,10).  In this 
body of work, SPR-based fragment screening identified novel small molecules that bound to tip proteins 
LcrV (Yersinia pestis) and PcrV (Pseudomonas aeruginosa).  Binding of the fragment hit to their cognate 
protein was validated and characterized using NMR spectroscopy, described in Chapter 3.  Analysis of 
15N and ILV methyl-based NMR titrations of the tip proteins with the hit fragments revealed these small 
molecules, although chemically distinct, perturbed a similar surface – the N-terminal globular domain of 
the V-tip proteins (30), suggesting this surface to be a potential hotspot for drug interaction.  Chemical 
inhibitors of the T3SS have been identified, but the specific molecular targets in the T3SS for most of the 
compounds are not known (9,31).  The novel scaffolds that we have identified are the first small 
molecules shown to directly bind to the virulent tip proteins LcrV and PcrV and could potentially be 
developed into T3SS protein-protein interaction inhibitors. 
  
Our compounds showed weak ‘mM’ range binding affinities to the tip proteins LcrV and PcrV.  
However, in vivo inhibition likely requires tighter binding compounds.  Future fragment building studies 
would be needed to design high-affinity specific binders of the tip proteins (32).  The potent compounds 
should subsequently be tested for their ability to disrupt protein-protein interactions and inhibit the T3SS 
in the in vitro binding assays and functional bacterial invasion assay.  
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4.2.2.  Implications of the ILV methyl assignments of LcrV 
 
NMR characterization of the binding of small molecules to the tip proteins LcrV and PcrV 
require resonance assignments (backbone amide or side chain methyl ILV) to identify the surface(s) of 
the tip proteins involved in the interaction.  LcrV and PcrV are large proteins (~35 kDa) and tend to 
aggregate at high protein concentrations, making the NMR studies particularly challenging.  Side chain 
ILV methyl groups with favorable NMR relaxation properties and high sensitivity offer phenomenal 
probes to study structure, dynamics, and protein-ligand interactions (21).  Using mutagenesis, 
perdeuteration, 1H-1H NOEs from 3D-NOESY experiments, and a high-resolution crystal structure of 
LcrV, near complete ILV methyl assignments were obtained for LcrV (Chapter 3).  The NMR 
assignments presented in this body of work are the only available assignments from the entire Yersinia 
family of the T3SS tip proteins.  These assignments were successfully used in the identification and 
characterization of the LcrV-small molecule interaction surfaces and would facilitate further molecular 
interaction studies of the tip protein LcrV. 
 
 Prior to the secretion of LcrV to assemble the Yersinia T3SS tip complex, it remains bound to a 
small chaperone protein LcrG in the bacterial cytoplasm.  The tip-chaperone interactions in the Yersinia 
family of T3SS are important for the regulation of effector secretion (33,34).  LcrV-LcrG protein-protein 
interactions have been studied previously using NMR (33,35), however, due to the lack of resonance 
assignments, interaction surfaces of the chaperone protein LcrG on the tip protein LcrV could not be 
determined.  The ILV methyl assignments of LcrV, presented herein, allowed identification of the LcrV-
LcrG binding surfaces.  Analysis of the ILV methyl titrations revealed that a large surface on LcrV was 
perturbed upon the binding of LcrG (Figure 4-3).  This is not very surprising since LcrG is a partially 
folded and an intrinsically flexible protein (35), and flexible proteins usually provide a large surface area 
for interaction compared to globular proteins (36).  Furthermore, previous interaction studies have shown 
that entire length of the chaperone protein LcrG is involved in binding to the tip protein LcrV and even 
 92 
upon the LcrV-LcrG complex formation, LcrG remains flexible and does not undergo a disorder-to-order 
transition (33,35).  Taken together, it seems likely that the binding of LcrG to LcrV may involve a large 
interaction surface on LcrV.  These results highlight the significance of the ILV methyl assignments of 





Figure 4-3.  ILV titrations of tip protein LcrV with chaperone LcrG.  (A) Overlay of four 2D 1H-13C 
HSQC spectra of ILV-labeled LcrV titrated with increasing mole ratios of LcrG.  Affected residues 
displaying reduction in peak intensity are marked with an asterisk and new peaks appearing upon 
complex formation are shown with a box.  (B) ILV resonances of LcrV affected upon the binding of LcrG 




To better appreciate the structural basis of the tip-chaperone interactions of the T3SS, NMR 
titrations have also been performed on the Pseudomonas aeruginosa tip protein PcrV and the cognate 
chaperone PcrG, the homologs of Yersinia pestis LcrV and LcrG, respectively (37) (Figure 4-4).  Both 
side chain methyl ILV and backbone amide titrations show a large number of PcrV resonances being 
affected upon the binding of PcrG, similar to the LcrV-LcrG interactions.  While some resonances display 
peak broadening, others show changes in the peak position.  Additionally, new complex peaks upon the 
binding of PcrG are also evident (Figure 4-4).  Such complex NMR exchange behavior suggests that the 
chaperone binding is likely accompanied with conformational changes in the tip protein PcrV.  Using the 
available ILV assignments of PcrV, the identified affected residues were mapped onto the bottom and top 
of the coiled-coil domain (Figure 4-4B).  A detailed characterization of this intricate interaction would 
require NMR (amide and ILV) assignments of the free and chaperone-bound PcrV (new peaks upon 
complex formation).  In this direction, high-quality 3D-NOESY NMR data on perdeuterated methyl-ILV 
labeled PcrV has been collected (Figure 4-5A).  Given the large sizes of the tip proteins, perdeuteration 
was essential to observe the NOEs (38,39).  For comparison, a non-deuterated sample displayed broad 
resonances with minimal NOEs (Figure 4-5B).  However, in the absence of a high-resolution structure of 
PcrV, it is challenging to complete the methyl ILV assignments utilizing the NOESY data only.  In future, 
the NOE restraints may be used in combination with computational modeling tools to build a de novo 




Figure 4-4.  NMR determination of PcrV-PcrG tip-chaperone protein-protein interactions from the 
Pseudomonas T3SS.  (A) ILV titrations of PcrV and PcrG.  Affected residues are marked with an asterisk 
(peak intensity reduction), or arrow (change in peak position).  New peaks are shown with a box.  (B) ILV 
resonances affected upon PcrV-PcrG complex formation mapped onto the I-TASSER model of PcrV.  (C) 




Figure 4-5.  Perdeuteration is necessary with large proteins to observe NOEs.  (A) A perdeuterated 
13C-ILV labeled sample of PcrV at 0.3 mM concentration, lyophilized and re-suspended in 100% D2O, 
and (B) A non-deuterated 13C-ILV labeled sample of PcrV at 0.3 mM concentration, lyophilized and re-
suspended in 100% D2O.  
  
 
4.3.  References 
 
1. Cornelis, G. R. (2006) The type III secretion injectisome. in Nat Rev Micro, Nature Publishing 
Group 
2. Coburn, B., Sekirov, I., and Finlay, B. B. (2007) Type III Secretion Systems and Disease. in Clin. 
Microbiol. Rev.  
































































3. Galán, J. E., Lara-Tejero, M., Marlovits, T. C., and Wagner, S. (2014) Bacterial type III secretion 
systems: specialized nanomachines for protein delivery into target cells. in Annu. Rev. Microbiol.  
4. Chatterjee, S., Chaudhury, S., McShan, A. C., Kaur, K., and De Guzman, R. N. (2013) Structure 
and Biophysics of Type III Secretion in Bacteria. in Biochemistry  
5. Kubori, T., Matsushima, Y., Nakamura, D., Uralil, J., Lara-Tejero, M., Sukhan, A., Galan, J. E., 
and Aizawa, S. I. (1998) Supramolecular structure of the Salmonella typhimurium type III protein 
secretion system. in Science  
6. Schraidt, O., and Marlovits, T. C. (2011) Three-dimensional model of Salmonella's needle 
complex at subnanometer resolution. in Science  
7. Kosarewicz, A., Konigsmaier, L., and Marlovits, T. C. (2012) The blueprint of the type-3 
injectisome. in Philosophical Transactions of the Royal Society B: Biological Sciences  
8. Demers, J.-P., Habenstein, B., Loquet, A., Kumar Vasa, S., Giller, K., Becker, S., Baker, D., 
Lange, A., and Sgourakis, N. G. (2014) High-resolution structure of the Shigella type-III 
secretion needle by solid-state NMR and cryo-electron microscopy. in Nat Commun  
9. Keyser, P., Elofsson, M., Rosell, S., and Wolf-Watz, H. (2008) Virulence blockers as alternatives 
to antibiotics: type III secretion inhibitors against Gram-negative bacteria. in J Intern Med  
10. Duncan, M. C., Linington, R. G., and Auerbuch, V. (2012) Chemical inhibitors of the type three 
secretion system: disarming bacterial pathogens. in Antimicrobial Agents and Chemotherapy  
11. Hume, P. J., McGhie, E. J., Hayward, R. D., and Koronakis, V. (2003) The purified Shigella IpaB 
and Salmonella SipB translocators share biochemical properties and membrane topology. Mol. 
Microbiol. 49, 425-439 
12. McGhie, E. J. E., Hume, P. J. P., Hayward, R. D. R., Torres, J. J., and Koronakis, V. V. (2002) 
Topology of the Salmonella invasion protein SipB in a model bilayer. Mol. Microbiol. 44, 1309-
1321 
13. Rodriguez-Castañeda, F., Haberz, P., Leonov, A., and Griesinger, C. (2006) Paramagnetic 
tagging of diamagnetic proteins for solution NMR. Magn. Reson. Chem. 44, S10-S16 
14. Otting, G. (2010) Protein NMR Using Paramagnetic Ions. in Annu. Rev. Biophys.  
15. Johnson, S., Roversi, P., Espina, M., Olive, A., Deane, J. E., Birket, S., Field, T., Picking, W. D., 
Blocker, A. J., Galyov, E. E., Picking, W. L., and Lea, S. M. (2007) Self-chaperoning of the Type 
III Secretion System Needle Tip Proteins IpaD and BipD. in J Biol Chem  
16. Cheung, M., Shen, D.-K., Makino, F., Kato, T., Roehrich, A. D., Martinez-Argudo, I., Walker, M. 
L., Murillo, I., Liu, X., Pain, M., Brown, J., Frazer, G., Mantell, J., Mina, P., Todd, T., Sessions, 
R. B., Namba, K., and Blocker, A. J. (2015) Three-dimensional electron microscopy 
reconstruction and cysteine-mediated crosslinking provide a model of the type III secretion 
system needle tip complex. Mol. Microbiol. 95, 31-50 
17. Dickenson, N. E., Arizmendi, O., Patil, M. K., Toth, I., Ronald T, Middaugh, C. R., Picking, W. 
D., and Picking, W. L. (2013) N-Terminus of IpaB Provides a Potential Anchor to the 
ShigellaType III Secretion System Tip Complex Protein IpaD. Biochemistry 52, 8790-8799 
18. Rathinavelan, T., Lara-Tejero, M., and Lefebre, M. (2014) NMR Model of PrgI–SipD Interaction 
and Its Implications in the Needle-Tip Assembly of the Salmonella Type III Secretion System. 
Journal of molecular biology  
19. Rathinavelan, T., Tang, C., and De Guzman, R. N. (2011) Characterization of the interaction 
between the Salmonella type III secretion system tip protein SipD and the needle protein PrgI by 
paramagnetic relaxation enhancement. in J Biol Chem  
20. Kay, L. E. (2011) Solution NMR spectroscopy of supra-molecular systems, why bother? A 
methyl-TROSY view. Journal of Magnetic Resonance 210, 159-170 
21. Tugarinov, V., and Kay, L. E. (2005) Methyl Groups as Probes of Structure and Dynamics in 
NMR Studies of High-Molecular-Weight Proteins. in ChemBioChem  
22. Faudry, E., Vernier, G., Neumann, E., Forge, V., and Attree, I. (2006) Synergistic pore formation 
by type III toxin translocators of Pseudomonas aeruginosa. Biochemistry 45, 8117-8123 
 97 
23. Myeni, S. K., Wang, L., and Zhou, D. (2013) SipB-SipC Complex Is Essential for Translocon 
Formation. PLoS One 8, e60499 
24. Birket, S. E., Harrington, A. T., Espina, M., Smith, N. D., Terry, C. M., Darboe, N., Markham, A. 
P., Middaugh, C. R., Picking, W. L., and Picking, W. D. (2007) Preparation and characterization 
of translocator/chaperone complexes and their component proteins from Shigella flexneri. 
Biochemistry 46, 8128-8137 
25. Lokareddy, R. K., Lunelli, M., Eilers, B., Wolter, V., and Kolbe, M. (2010) Combination of Two 
Separate Binding Domains Defines Stoichiometry between Type III Secretion System Chaperone 
IpgC and Translocator Protein IpaB. Journal of Biological Chemistry 285, 39965-39975 
26. Lunelli, M., Lokareddy, R. K., Zychlinsky, A., and Kolbe, M. (2009) IpaB-IpgC interaction 
defines binding motif for type III secretion translocator. Proceedings of the National Academy of 
Sciences 106, 9661-9666 
27. Chen, X., Choudhari, S. P., Kumar, P., Toth, R. T., Kim, J. H., Van Roosmalen, M. L., 
Leenhouts, K., Middaugh, C. R., Picking, W. L., and Picking, W. D. (2015) Biophysical 
Characterization of the Type III Secretion System Translocator Proteins and the Translocator 
Proteins Attached to Bacterium-Like Particles. J Pharm Sci  
28. Romano, F. B., Rossi, K. C., Savva, C. G., and Holzenburg, A. (2011) Efficient Isolation of 
Pseudomonas aeruginosa Type III Secretion Translocators and Assembly of Heteromeric 
Transmembrane Pores in Model Membranes - Biochemistry (ACS Publications). Biochemistry  
29. CDC. (2016) Antimicrobial resistance.   
30. Chaudhury, S., Battaile, K. P., Lovell, S., Plano, G. V., and De Guzman, R. N. (2013) Structure 
of the Yersinia pestistip protein LcrV refined to 1.65 Å resolution. in Acta Crystallogr. Sect. F 
Struct. Biol. Cryst. Commun., International Union of Crystallography 
31. McShan, A. C., and De Guzman, R. N. (2015) The bacterial type III secretion system as a target 
for developing new antibiotics. in Chem Biol Drug Des  
32. Scott, D. E., Ehebauer, M. T., Pukala, T., Marsh, M., Blundell, T. L., Venkitaraman, A. R., Abell, 
C., and Hyvönen, M. (2013) Using a fragment-based approach to target protein-protein 
interactions. ChemBioChem 14, 332-342 
33. De Guzman, R. N., Egan, S. M., Davido, D., Hefty, S., Richter, M., and Weis, D. (2013) 
Structural Studies of Chaperones and Chaperone-Tip interactions from the type III secretion 
systems of Yersinia and Pseudomonas.  
34. DeBord, K. L., Lee, V. T., and Schneewind, O. (2001) Roles of LcrG and LcrV during Type III 
Targeting of Effector Yops by Yersinia enterocolitica. J. Bacteriol. 183, 4588-4598 
35. Chaudhury, S., de Azevedo Souza, C., Plano, G. V., and De Guzman, R. N. (2015) The LcrG Tip 
Chaperone Protein of the Yersinia pestis Type III Secretion System Is Partially Folded. J Mol 
Biol 427, 3096-3109 
36. Babu, M. M., van der Lee, R., de Groot, N. S., and Gsponer, J. (2011) Intrinsically disordered 
proteins: regulation and disease. Current Opinion in Structural Biology 21, 432-440 
37. Chaudhury, S., Nordhues, B. A., Kaur, K., Zhang, N., and De Guzman, R. N. (2015) Nuclear 
Magnetic Resonance Characterization of the Type III Secretion System Tip Chaperone Protein 
PcrG of Pseudomonas aeruginosa. in Biochemistry, American Chemical Society 
38. Barrett, P. J., Chen, J., Cho, M.-K., Kim, J.-H., Lu, Z., Mathew, S., Peng, D., Song, Y., Van 
Horn, W. D., Zhuang, T., Sönnichsen, F. D., and Sanders, C. R. (2013) The Quiet Renaissance of 
Protein Nuclear Magnetic Resonance. in Biochemistry  
39. Tzeng, S.-R., Pai, M.-T., and Kalodimos, C. G. (2012) NMR studies of large protein systems. 







This page intentionally left blank.  
 
 99 
Chapter 5: NMR Identification of a New SUMO-Interacting Motif in SUMO 
E3 Ligase PIASy 
 
Kawaljit Kaur, Yoshiaki Azuma, and Roberto N. De Guzman 
 
Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA
 100 
5.1.  Abstract 
 
SUMO conjugation is a reversible post-translational modification process implicated in the 
regulation of gene transcription, DNA repair, and cell cycle.  SUMOylation depends on the sequential 
activities of E1 activating, E2 conjugating, and E3 ligating enzymes.  SUMO E3 ligases enhance transfer 
of SUMO from the charged E2 enzyme to the substrate.  PIASy, a member of the Siz/PIAS RING family 
of SUMO E3 ligases, is essential for mitotic SUMOylation of chromosomal proteins, yet the determinants 
required for SUMO conjugation by PIASy are not well defined.  Here, using NMR chemical shift 
mapping and mutational analysis, we identified a new SUMO-interacting motif (SIM) in PIASy.  In vitro 
SUMOylation assays illustrated significant role of the new SIM for a fully active SUMO E3 ligase.  Our 
results provide novel insights into the mechanism of PIASy-mediated SUMO conjugation.  With the 
identification of a new SIM, PIASy adds to the growing list of SUMO E3 ligases containing tandem SIMs 
important for the E3 ligase activity. 
 
 
5.2.  Introduction 
 
Covalent attachment of small ubiquitin-like modifier (SUMO) to protein targets is an important 
post-translational modification that regulates multiple cellular processes, including transcription, nuclear 
transport, DNA repair, and chromosome segregation (1,2).  Vertebrates express at least three functional 
SUMO isoforms, namely, SUMO-1, SUMO-2, and SUMO-3 that can conjugate to other proteins.  
SUMO-1 shares less than 50% sequence identity to other isoforms, while SUMO-2 and SUMO-3 are 
virtually equivalent with 97% sequence identity and are commonly referred as SUMO-2/3 (1-3).  Similar 
to ubiquitylation, SUMO proteins are typically conjugated to target lysine residue of the substrate by the 
sequential action of three enzymes: an E1 activating enzyme (Uba2/Aos1), an E2 conjugating enzyme 
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(Ubc9), and an E3 ligase.  A SUMO E3 ligase stabilizes and optimally positions the thioester charged 
E2~SUMO complex to catalyze the transfer of SUMO from charged E2 to the substrate (2-5). 
 
 All SUMOylation reactions utilize the same E1 and E2 enzymes, however, several different 
classes of SUMO E3 ligases have been identified (2,3).  Most known SUMO E3 ligases, including Siz 
and PIAS proteins, RanBP2, polycomb protein Pc2, SLX4, and recently characterized ZNF451 possess 
one or more SUMO-interacting motifs (SIMs) to mediate non-covalent interactions with SUMO (2,3,5-9).  
In most cases, SIMs are required for the E3 ligase activity and play an important role in positioning the 
donor SUMO from E2~SUMO complex for efficient SUMO discharge and catalysis.  Typically, SIMs are 
short motifs that harbor a core sequence consisting of three or four hydrophobic residues (I, L, V) with an 
acidic or polar residue at position 2 or 3 (V/I-X-V/I-V/I or V/I-V/I-X-V/I/L) (10-13).  The hydrophobic 
core of SIM is often flanked by a stretch of acidic amino acids that can promote electrostatic SUMO-SIM 
interactions (10,14).  Structural studies have demonstrated that SIM can adopt a parallel or antiparallel -
strand conformation upon binding in the hydrophobic groove formed by 2-strand and 1-helix of 
SUMO proteins (5,10,14,15). 
 
 Members of the Siz/PIAS family of SUMO E3 ligases include human PIAS proteins (PIAS1, 
PIAS2/x and 2/x, PIAS3, and PIAS4/y) and their yeast homologs (Siz1, Siz2, Mms21, and Zip3) 
(2,4,9,16).  Siz/PIAS ligases contain several conserved regions (Figure 5-1A), including an N-terminal 
SAP (scaffold attachment factor-A/B, acinus and PIAS) domain involved in AT-rich DNA binding, a 
PINIT domain important for substrate recognition and subcellular localization, a SP-RING domain related 
to ubiquitin RING E3 ligases to recruit E2 Ubc9, and a C-terminal SIM for SUMO binding (2,3,9).  
 
Previous biochemical and structural studies in yeast SUMO E3 ligase Siz1 displayed a fragment 
comprising the PINIT, the SP-RING and a C-terminal region of SP-RING (named SP-CTD) as sufficient 
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to facilitate SUMO conjugation to the target substrates (4,17).  The C-terminal SIM was dispensable for 
the Siz1 ligase activity, and instead, an acidic patch in the SP-CTD was suggested to be important for the 
donor SUMO positioning and activation of the E2~SUMO complex during Siz1-mediated SUMOylation 
(4).   Intriguingly, other members of the Siz/PIAS ligase family do not contain a similar acidic domain in 
their SP-CTD region (4).  We have previously shown that SUMO E3 ligase PIASy is essential for 
SUMO-2/3 conjugation of mitotic chromosomal proteins, DNA topoisomerase II (TopoII and poly 
(ADP-ribose) polymerase 1 (PARP1) (16,18,19).  To understand the SIM-dependence and mechanism of 
PIASy-mediated SUMOylation, we examined a series of PIASy truncations for their ability to enhance 
SUMOylation of TopoIIand PARP1 using the established in vitro SUMOylation assay.  The results 
assisted in the identification of a new SIM in PIASy.  The new SIM was validated and characterized using 
NMR spectroscopy.  Mutational analysis revealed significance of the new SIM in efficient PIASy-
mediated SUMO conjugation. 
 
 
5.3.  Methods 
 
5.3.1.  Cloning, Expression, and Protein Purification   
 
Xenopus laevis PIASy sharing 85% sequence similarity to the human homolog (Figure 5-5) was 
used in these studies.  Design of expression plasmids for N-terminal His6-tagged human SUMO-2-GG, 
SUMO-3-GG, and Xenopus full-length PIASy have been previously described (16,20).  C-terminal 
truncations of PIASy (N480, N454, and N414, shown in Figure 1) and PIASy NMR constructs (287-454 
and 287-501, shown in Figure 5-2 and 5-3) were amplified by PCR from full-length construct and 
subcloned into pET28a using EcoRI and XhoI restriction sites.  PIASy fragments 409-454 and 409-501, 
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shown in Figure 5-4 and 5-6, were obtained by digesting PIASy 287-454 and 287-501 in pET28a with 




Figure 5-1.  In vitro SUMO E3 ligase activity of C-terminal deletions of PIASy.  (A) Schematic 
diagram with conserved domains of the Siz/PIAS E3 ligase family shown as: SAP (vertical lines), PINIT 
(solid black), SP-RING (grid), SIM (blue), and S/DE (horizontal lines).  Solid bars below the schematic 
indicate PIASy truncation constructs tested in the SUMOylation assay.  Time course for SUMO 
modification of (B) TopoII, and (C) PARP1 with the indicated PIASy truncation construct in the in vitro 
SUMOylation assay.  SUMOylated and unmodified forms of TopoII and PARP1 are shown with bracket 




Plasmids were freshly transformed in E. coli BL21 (DE3) cells and grown in 1 liter of culture 
media containing kanamycin at 30 g/ml.  15N-labeled SUMO-3 was expressed in M9 minimal media 
supplemented with 1 g of 15N-ammonium chloride.  Unlabeled SUMO-3 (for fluorescence polarization 
studies) and PIASy fragments (for NMR studies) were obtained by cell growth in LB media.  PIASy 
constructs containing the RING domain were also supplied 0.1 mM ZnSO4 before and after induction.  
Cells were grown at 37 °C until OD600 was ~ 0.7 to 0.8, induced with 0.5 mM isopropyl-β-D-
thiogalactopyranoside (IPTG), and cell growth was continued overnight to a final OD600 ~ 2.5 (~2.1 for 
PIASy constructs) in a 15 °C shaker incubator.  Cells were harvested by centrifugation (4000 rpm, 10 
min), resuspended in ~ 30 ml binding buffer (500 mM NaCl, 20 mM Tris HCl pH 8.0, 5 mM imidazole), 
and lysed by sonication.  Cellular debris was removed by centrifugation (13000 rpm, 10 min), and 600 l 
of 5% (v/v) polyethyleneimine was added to the supernatant to precipitate the nucleic acids.  After 
another centrifugation (13000 rpm, 10 min), the supernatant was loaded to a pre-charged Ni2+ column and 
His6-tagged recombinant proteins were purified using standard nickel affinity chromatography procedure.  
Elution fractions containing purified protein were pooled and dialyzed in NMR buffer (100 mM NaCl, 10 
mM NaPO4 pH 6.8, and 5 mM DTT).  Proteins were concentrated using Amicon Ultra 3K centrifugal 
filter (Millipore) and concentrations were determined by A280.  Recombinant proteins used in the 
SUMOylation assays, the E1 complex (Uba2/Aos1), E2 Ubc9, PIASy (full-length, truncation and mutant 
constructs), PARP1, TopoII, and SUMO-2 were expressed and purified same as previously (16,18-20).  
 
5.3.2.  Site-directed mutagenesis    
 
PIASy constructs with mutations in the SIM region (PIASy 409-454 mut, O-SIM, N-SIM, and 
W-SIM, as shown in Figure 5-4 and 5-7) were constructed using QuikChange mutagenesis kit 
(Stratagene).  All mutations were verified by DNA sequencing.  Expression and purification of the 
mutants were carried out as described above. 
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5.3.3.  In vitro SUMOylation assay   
 
SUMOylation reactions were performed as previously (18,19).  Briefly, 5 M SUMO-2, 2 mM 
ATP, 20 nM E1, 30 nM E2, 20 nM PIASy (different constructs as shown in figure), and 500 nM T7-
tagged PARP1 or TopoII in reaction buffer (20 mM HEPES pH 7.8, 100 mM NaCl, 5 mM MgCl2, 
0.05% Tween-20, 5% glycerol, and 0.5 mM DTT) were incubated at 25 °C for 1 hour.  At the indicated 
times, aliquots were removed, mixed with SDS-PAGE loading buffer and boiled.  Samples were resolved 
by SDS-PAGE and analyzed by western blotting using HRP-conjugated anti-T7 monoclonal antibody.  
 
5.3.4.  NMR Spectroscopy   
 
NMR data were acquired at 25 °C on a Bruker Avance III 600 MHz spectrometer equipped with 
TXI-RT probe.  Data processing and analysis were carried out using NMRPipe (21) and NMRView (22), 
respectively.  For NMR chemical shift mapping, 2D 1H-15N HSQC spectra were acquired using 0.2 mM 
15N-labeled SUMO-3 titrated with increasing molar ratios of unlabeled PIASy (indicated construct).  All 
titration samples contained 10% (v/v) D2O.  The published backbone amide assignment of SUMO-2/3 
was used in the analysis (10,23).  Weighted CSD was calculated using 0.5[(H)2 + (N/5)2]1/2 (24).  
Residues perturbed during the titrations were mapped onto the crystal structure of SUMO-3 (PDB ID: 
1U4A). 
 
5.3.5.  Fluorescence Polarization (FP)   
 
Purified SUMO-3 and PIASy 287-454 were dialyzed into 1X PBS buffer (phosphate buffered 
saline, pH 7.4) overnight.  The single native cysteine of SUMO-3 (residue 47) was utilized to covalently 
attach the fluorophore, fluorescein-maleimide (FM), following manufacturer’s protocol (Invitrogen).  
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Briefly, a 20-fold molar excess of FM prepared in dimethylsulfoxide was added to the TCEP-reduced 
protein and allowed to react in dark at room temperature for ~ 3 hours.  The unbound dye was removed 
by extensive dialysis in PBS, followed by passage through a 3K centrifugal filter (Millipore).  Increasing 
concentrations of PIASy (0-360 M) were titrated into 25 nM FM-labeled SUMO-3.  Samples were 
incubated at room temperature for 30 min and FP was measured with excitation and emission 
wavelengths of 492 nm and 515 nm, respectively using a Varian Cary Eclipse Fluorescence 
Spectrophotometer.  G-factor corrected polarization values were obtained using formula: p = (IVV – 
G*IVH)/( IVV + G*IVH).  Background fluorescence was subtracted from the average of 5 data points and the 
change in millipolarization (mP) was plotted against increasing concentrations of PIASy.  The 




5.4.  Results 
 
5.4.1.  SUMO ligase activity of C-terminal truncation constructs of PIASy   
 
We have previously demonstrated the crucial role of PIASy in SUMO-2/3 modification of mitotic 
substrates TopoII and PARP1 (16,18,19).  To identify the determinants required for SUMO-2/3 
modification by PIASy, we tested various C-terminal deletions of PIASy (Figure 5-1A) in the established 
in vitro reconstituted SUMOylation assay.  At physiological concentration of the SUMOylation enzymes, 
PIASy N414 (a fragment lacking 87 C-terminal residues) was inefficient in SUMOylating both TopoII 
and PARP1 (Figure 5-1B, 5-1C).  The extent of SUMO conjugation using N414 was almost similar to 
the activity observed in E3-independent reaction (last two lanes, Figure 5-1B, 5-1C).  Next, we examined 
a longer PIASy construct, N454 that lacked the known C-terminal SIM but retained all the components 
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previously reported as sufficient for the ligase activity of Siz1, PIAS homolog in yeast (4,17).  
Interestingly, though at a lower efficiency compared to full length PIASy (WT), SIM-less N454 was 
capable of SUMOylating both the mitotic substrates (Figure 5-1B, 5-1C).  Consistent with the previous 
observation in Siz1 (4), inclusion of the C-terminal SIM and the flanking acidic domain (PIASy N480) 
further enhanced the SUMO conjugation (Figure 5-1B, 5-1C). 
 
5.4.2.  PIASy lacking known C-terminal SIM interacts with SUMO   
 
Both PIASy N414 and N454 could recruit E2 Ubc9 through the SP-RING domain, however only 
N454 stimulated in vitro SUMO conjugation as an active ligase (Figure 5-1).  Previous studies have 
revealed that efficient E3-mediated SUMO conjugation requires optimal positioning of both E2 and 
SUMO from the E2~SUMO thioester complex (4-7,25).  To determine whether the SIM-less N454 
orients the E2~SUMO complex for productive catalysis by additional stabilization of SUMO, we tested 
the direct binding between SUMO and the SIM-less PIASy using NMR spectroscopy.  A shorter 
construct of PIASy, 287-454 (Figure 5-2A) due to better expression compared to N454, was more 
amenable to NMR and thus used in the interaction studies.  15N-labeled SUMO-3 was titrated with 
increasing concentrations of unlabeled PIASy 287-454 at 1:0, 1:0.5, 1:1, and 1:2 molar ratios, and the 
titration was monitored by acquiring 2D 1H-15N HSQC spectra (Figure 5-2B).  The stepwise addition of 
SIM-less PIASy 287-454 resulted in peak broadening of specific resonances of SUMO-3 (Figure 5-2B) 
indicating interaction in the intermediate exchange NMR time scale.  To identify the SUMO-3 residues 
that were perturbed the most by PIASy 287-454, we calculated the peak intensity ratio (I1:1/I1:0) for each 
non-overlapped SUMO-3 peak at a SUMO-3:PIASy 287-454 molar ratio of 1:1 (Figure 5-2C).  Residues 
displaying significant peak intensity reduction (average intensity minus a standard deviation) included 
S27, Q30, F31, K41, L42, A45, Y46, D62, E78, and T82.  The affected residues were mapped onto the 
structure of SUMO-3 (Figure 5-2D).  Surprisingly, even though PIASy 287-454 lacks the known C-
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terminal SIM, majority of the affected residues clustered together spatially in the 2-strand and 1-helix 
of SUMO-3, the well characterized binding surface for the SIM on SUMO (10,12,14,15).  These results 
suggested existence of another SIM in PIASy within residues 287-454.  To gain further insights into the 
SUMO-PIASy 287-454 interaction, we conducted a fluorescence polarization based binding assay with 
fluorescein-maleimide labeled SUMO-3.  PIASy 287-454 interacted with SUMO-3 with an apparent Kd 
of ~ 81 M (Figure 5-2E).  The value obtained is consistent with the observed intermediate exchange 
NMR behavior and previously reported dissociation constants for other SUMO-SIM interactions, which 
are in the 1-120 M range (6,10,12,15,26). 
 
In addition to PIASy 287-454, we also performed NMR titrations of 15N SUMO-3 with unlabeled 
PIASy 287-501 (Figure 5-3A).  As expected, incorporation of the known C-terminal SIM and the acidic 
domain resulted in more pronounced chemical shift perturbations when compared to PIASy 287-454 
(Figure 5-3B).  Stepwise addition of PIASy 287-501 caused concentration dependent decrease in 
intensities of SUMO-3 peaks.  Some SUMO-3 residues along with peak intensity reduction also showed 
subtle shifts in peak positions (e.g. R35, K41, Y46, and N67) and several peaks broadened beyond 
detection during the titration (Figure 5-3B).  Although most SUMO-3 residues showed some degree of 
line broadening from the beginning of titration, which is not uncommon with the formation of a high 
molecular weight complex (SUMO-3, 13 kDa; PIASy 287-501, 28 kDa) slowing down the tumbling rate 
(27), specific residues were more affected than the others as illustrated by peak intensity ratio graph 
(Figure 5-3C).  The strongly affected SUMO-3 residues by PIASy 287-501 were identical to the residues 
affected by PIASy 287-454 and mapped to 2-strand and 1-helix, the SIM binding surface on the 




Figure 5-2.  Analysis of the interaction of SUMO-3 with PIASy lacking the known SIM.  (A) PIASy 
schematic as in Figure 1A, with solid bar indicating the fragment, 287-454, used in NMR and FP 
experiment.  (B) 2D 1H-15N HSQC spectra of 15N-labeled SUMO-3 titrated with increasing molar ratios of 
PIASy 287-454.  Expanded sections of representative SUMO-3 residues affected upon the binding of 
PIASy 287-454 are shown on right.  (C) Plot of relative peak intensity for all assigned, non-overlapping 
SUMO-3 resonances in the ligand bound versus free form (I1:1/I1:0).  Gray and red lines depict mean and 
one standard deviation from the mean (-1), respectively.  (D) SUMO-3 residues displaying significant 
peak intensity reduction upon complex formation with PIASy 287-454 are highlighted red.  (E) 
Fluorescence polarization binding assay of FM-labeled SUMO-3 titrated with increasing concentrations 




Figure 5-3.  NMR binding study of SUMO-3 and PIASy 287-501.  (A) Schematic of PIASy as in 
Figure 1A, with solid bar indicating the fragment used in the experiment.  (B) 2D 1H-15N HSQC spectra 
of 15N-labeled SUMO-3 titrated with increasing amounts of PIASy 287-501.  Expanded sections of 
selected SUMO-3 residues affected by PIASy 287-501 are shown on right.  (C) Relative peak intensity 
graph for SUMO-3 resonances in the ligand bound versus free state (I1:0.25/I1:0), where, gray and red lines 
correspond to the mean and one standard deviation from the mean (-1), respectively.  (D) Affected 
SUMO-3 residues upon the binding of PIASy 287-501 are highlighted (red, significant peak intensity 
reduction; orange, significant change in the peak position). 
 
5.4.3.  A new SIM in SUMO E3 ligase PIASy   
 
NMR chemical shift mapping results for 15N SUMO-3 titrations with PIASy 287-454 indicated an 
additional SIM in PIASy (Figure 5-2).  Using a SIM-prediction web server (28), we found PIASy 287-
454 fragment to contain a high probability SIM (herein, termed as new SIM) within residues 417-435 
(Figure 5-4A).  The new SIM showed complete sequence conservation across many different organisms 
from amphibian to the human PIASy (Figure 5-5).  Comparable to characteristic SIM sequences that bind 
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SUMO in antiparallel orientation (6,10,11,26), the new PIASy SIM harbor a conserved hydrophobic core 
‘ILVL’ that is preceded by few acidic and putative phosphorylatable serine residues (Figure 5-4A).  
However, unlike a signature SIM, the new SIM lacks a long contiguous stretch of acidic residues.  To 
confirm the role of new SIM in SUMO binding, we subcloned PIASy region containing the new SIM 
fragment (PIASy 409-454 ‘wt’) and mutated three critical hydrophobic core SIM residues (PIASy 409-
454 ‘mut’) to alanines (Figure 5-4A).  In comparison to the earlier SP-RING containing fragments, 
PIASy 409-454 showed greater stability and solubility, and thus, was ideal for NMR studies.  NMR 
binding experiments were performed using 15N-labeled SUMO-3 with either ‘wt’ or ‘mut’ PIASy 409-454 
new SIM fragment (Figure 5-4).  Besides gradual peak intensity reduction, addition of unlabeled ‘wt’ 
PIASy 409-454 resulted in concentration dependent changes in peak position for selective SUMO-3 
resonances (Figure 5-4B, 5-4C), indicating interaction at the edge of fast intermediate exchange NMR 
time scale.  In contrast, NMR titrations with ‘mut’ PIASy 409-454 barely induced any discernible 
chemical shift perturbations on SUMO-3 (Figure 5-4D, 5-4E), indicating the new SIM mutation 
interfered with the SUMO interaction.  Analysis of weighted chemical shift deviations (CSD, Figure 5-
4F) displayed that strongly affected residues upon binding of ‘wt’ PIASy 409-454 cluster clearly near the 
SIM binding groove of SUMO-3 (Figure 5-4G).  Together, the results highlight the importance of 
hydrophobic core of the new PIASy SIM in SUMO recognition. 
 
Next, we analyzed the binding of SUMO-3 with PIASy 409-501, construct encompassing old 
SIM and the acidic domain (Figure 5-6A).  Similar to the earlier titrations, identical SIM-binding 
residues of SUMO-3 were most strongly perturbed upon the addition of PIASy 409-501 (Figure 5-6B, 5-
6C, 5-6D).  Comparison of SUMO-3 titrations with PIASy 409-454 (new SIM alone) and PIASy 409-501 
(both SIMs) indicated that presence of both SIMs together conferred a higher magnitude of change in the 
chemical shift perturbations of selective SUMO-3 resonances, notably, even when using a much lower 
ligand concentration.  Important SUMO-3 SIM-binding residues, such as, Q30, F31, L42, A45, and Y46, 
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showed severe peak intensity reduction starting at 1:0.25 molar ratios and complete peak broadening by 




Figure 5-4.  Characterization of the binding of SUMO-3 and the new SIM of PIASy.  (A) PIASy 
schematic as in Figure 1A with new SIM in magenta.  Solid bar corresponds to the PIASy fragment, 409-
454, used in the experiment.  Sequence of the wild type ‘wt’ and mutant ‘mut’ PIASy construct is shown.  
(B) A section of 2D 1H-15N HSQC spectra of 15N-labeled SUMO-3 titrated with increasing molar ratios of 
wt PIASy 409-454 demonstrates specific SUMO-SIM binding.  (C) Expanded sections of selected 
SUMO-3 residues affected upon wt PIASy 409-454 binding.  (D) and (E) Similar to (B) and (C) for 
SUMO-3 titrations with mut PIASy 409-454.  (F) Plots of weighted CSD from titrations of SUMO-3 with 
wt PIASy 409-454 (top) and mut PIASy 409-454 (bottom).  Gray and red lines correspond to the mean 
and one standard deviation (+1) from the mean, respectively.  (G) Strongly affected SUMO-3 residues 




Figure 5-5.  Comparison of human and Xenopus PIASy.  (A) Sequence alignment of PIASy from 
Homo sapiens and Xenopus laevis.  Numbers above and below the alignment correspond to human 
(black) and Xenopus (orange) PIASy, respectively.  The old known SIM is shown in blue and the new 
SIM identified in this work is indicated in magenta.  Conserved serine and acidic residues preceding the 
new SIM are marked with green asterisk.  (B) Schematic of human and Xenopus PIASy displaying 
conserved domains of Siz/PIAS family of SUMO E3 ligases.  Numbers indicate boundaries between the 
domains.      
 
5.4.4.  New SIM is crucial in PIASy-mediated SUMOylation 
   
To evaluate the significance of the SIMs for the E3 ligase activity of PIASy, we mutated three 
essential core SIM residues to alanines to generate O-SIM (mutation in the old known SIM), N-SIM 
(mutation in the new SIM), and W-SIM (a double SIM mutant) in full-length PIASy as shown in Figure 
5-7A.  The mutants were examined for their ability to facilitate SUMO conjugation of PARP1 in the in 
vitro SUMOylation assay.  Interestingly, mutation of the old-SIM mutant (O-SIM) did not interfere with 
the role of PIASy and exhibited high SUMOylation levels comparable to the wild type (WT) PIASy 
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(Figure 5-7B, 5-7C).  However, the new SIM mutant (N-SIM) was significantly less efficient in 
mediating SUMO conjugation (Figure 5-7B, 5-7C). Indeed, there was almost negligible SUMOylation 
using N-SIM after 30 min of the reaction time.  Furthermore, a combinatorial mutation of old and new 
SIM (W-SIM) nearly abolished the ligase activity of PIASy (Figure 5-7B, 5-7C).  Collectively, our 





Figure 5-6.  NMR titrations of SUMO-3 and PIASy 409-501.  (A) Schematic of PIASy as in Figure 5-4, 
with solid bar indicating fragment used in the experiment.  (B) 2D 1H-15N HSQC spectra of 15N-labeled 
SUMO-3 titrated with increasing amounts of PIASy 409-501.  Expanded sections of representative 
SUMO-3 residues affected by the binding of PIASy 409-501 are on right.  (C) Relative peak intensity 
plot for SUMO-3 resonances in the ligand bound versus free state (I1:0.25/I1:0).  Gray and red lines depict 
mean and one standard deviation from the mean (-1), respectively.  (D) Affected SUMO-3 residues 
upon complex formation with PIASy 409-501 are highlighted (red, residues displaying significant peak 




Figure 5-7.  Significance of the new SIM of PIASy.  (A) Schematic of PIASy as in Figure 5-4, with 
solid bars illustrating different SIM mutations examined in the SUMOylation assay.  (B) Time course for 
SUMO modification of PARP1 with the indicated PIASy SIM mutant in the in vitro SUMO conjugation 
assay.  SUMOylated and unmodified forms of PARP1 are marked with bracket and bar, respectively.  The 
PIASy input is shown in the bottom panel.  (C) Quantification of the SUMO conjugation assay shown in 
B at the final time point.  Assay was performed in triplicate.  Error bars represent one standard deviation 
and asterisk indicates statistically significant differences from the WT activity. 
Data courtesy of Dr. Yoshiaki Azuma. 
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5.5.  Discussion 
 
In the current study, the combination of NMR binding studies and in vitro SUMOylation assays 
revealed a new SIM in PIASy that was found to be essential for efficient PIASy-dependent SUMO-2/3 
conjugation.  In contrast to the old SIM of PIASy (or the known SIM of other PIAS family members), the 
new SIM contains an uninterrupted core of four hydrophobic residues and lacks the conventional 
extended acidic residue stretch (Figure 5-5).  Previous SUMO-SIM interaction studies have described the 
hydrophobic core of SIM as a key mediator for SUMO binding (10,12,13).  Consistent with these findings, 
our NMR studies demonstrate that hydrophobic core residues of the new SIM are sufficient to establish 
binding to SUMO-3 and mutation of these critical residues abolishes binding (Figure 5-4).  Additionally, 
previous studies have highlighted the role of acidic residue tract surrounding the hydrophobic core of SIM 
in SUMO paralog binding specificity (10).  While presence of the negative charges in SIM has been 
shown to contribute more toward SUMO-1 binding, SIMs lacking the acidic stretch preferentially bind 
SUMO-2 (8,10).  Absence of the acidic residue stretch in the new SIM, together with the significant role 
of new SIM in PIASy-mediated SUMO conjugation (Figure 5-7), provides a likely explanation for the 
high preference of PIASy in mediating SUMO-2/3 conjugation over SUMO-1 to substrates TopoII and 
PARP1 (16,18,19).   
 
 In addition to the covalent interaction between E2 Ubc9 and SUMO (E2~SUMO thioester 
complex), the backside of Ubc9 can also recruit a second molecule of SUMO (E2-SUMO) through non-
covalent interactions (29,30).  Recent structural and biochemical studies have shown that SUMO E3 
ligase ZNF451 exploit these interactions to preferentially interact with two molecules of SUMO (donor 
SUMO from E2~SUMOD and backside E2-SUMO) via its tandem SIMs (6,7).  The first SIM in 
conjunction with the inter-SIM region positions the E2~SUMOD thioester complex for productive 
catalysis while the second SIM acts as an anchor to bind to the backside SUMO to facilitate poly-
SUMOylation (6,7).  Intriguingly, although PIAS proteins use the SP-RING domain to directly bind to E2 
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Ubc9, studies suggest that the SIM of PIAS proteins can also interact with the backside E2-SUMO to 
form a non-covalent ternary complex (31).  Taken together with the finding of the new SIM in PIASy, it 
seems plausible that analogous to ZNF451, the tandem SIM of PIASy may also simultaneously interact 
with the donor SUMO (E2~SUMOD) and the backside SUMO to mediate efficient SUMOylation.  In line 
with this notion, results of our NMR interaction studies with PIASy containing both the SIMs showed 
improved SUMO binding affinity (Figure 5-6) compared to the shorter construct consisting of new SIM 
only (Figure 5-4).  Specific SUMO-3 SIM-interacting residues including Q30, F31, L42, A45, and Y46, 
showed intense peak broadening even with very small amount of PIASy 409-501 (construct containing 
both the SIMs), however, these residues were in fast intermediate exchange NMR regime with the new 
SIM alone, suggesting weaker binding compared to PIASy 409-501.  Since both SIMs individually bind 
to the same surface on SUMO-3 through classical SUMO-SIM interactions (31), stronger perturbations 
observed with both SIM containing PIASy 409-501 is probably reflective of a synergistic effect occurring 
upon the binding of different SUMO-3 molecules to the tandem SIM.  Additionally, our in vitro 
SUMOylation assays confirmed that PIASy stimulated SUMO conjugation in a SIM-dependent manner 
and both SIMs are important for effective ligase activity.  Although, mutation of the new SIM (N-SIM) 
rendered SUMOylation slow and inefficient, probably implying its role in the donor SUMO 
(E2~SUMOD) positioning and chain initiation, mutation of both SIMs together (W-SIM, Figure 5-7) or 
deletion of the tandem SIM region (N414, Figure 5-1) eliminated PIASy E3 ligase activity.  In 
concordance, presence of both SIMs together resulted in the robust ligase activity of PIASy (N480, 
Figure 5-1).  Altogether, it is tempting to speculate that the SP-RING domain and the new SIM of PIASy 
may configure the E2~SUMOD thioester complex and the old SIM may engage the backside SUMO for 
efficient catalysis and SUMO conjugation by PIASy.  The functional importance of the new SIM in 
configuring donor SUMO is also in agreement with the previous Siz1 studies as both the new SIM of 
PIASy and Siz1 SP-CTD acidic patch regarded important for optimal donor SUMO positioning are 
located in the similar regions of the proteins (4). 
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Lastly, the N-terminal of the new SIM includes few conserved acidic and serine residues (Figure 
5-4) corresponding to the CK2 consensus phosphorylation site (32).  Phosphorylation of these residues 
could create a phosphoSIM that may enhance SUMO-SIM interactions by allowing additional 
electrostatic interactions (15).  This may also influence an antiparallel bound orientation for the new SIM 
by asymmetrically augmenting negative charges toward the N-terminal of the hydrophobic core of the 
new SIM (10,13,26). 
 
In conclusion, we have identified a new SIM (second C-terminal SIM) in PIASy that is critical 
for the efficient ligase activity and distinct from the other PIAS family proteins that contain a single SIM 
on their C-terminus.  Future in vivo analysis with mutant PIASy lacking individual SIM will provide 
further insight into the functional importance of multi-SIMs of E3 ligase PIASy. 
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6.1.  Abstract 
 
The RNA-binding protein Hu antigen R (HuR) binds to adenine- and uridine-rich elements 
(ARE) in the 3’- or 5’-untranslated region (UTR) of target mRNAs.  The HuR-ARE interactions stabilize 
many oncogenic mRNAs that play important roles in tumorigenesis.  Thus, small molecules that interfere 
with the HuR-ARE interaction could potentially inhibit cancer cell growth and progression.  We used 
fluorescence polarization (FP) based competition assay to identify that the compound azaphilone-9 (AZA-
9) derived from the fungal natural product asperbenzaldehyde is a potent inhibitor of HuR-ARE 
interaction.  Results from surface plasmon resonance (SPR) verified the direct binding of AZA-9 to HuR.  
NMR methods mapped the RNA-binding interface of HuR and identified the involvement of critical 
RNA-binding residues in binding AZA-9.  Further, computational methods modeled the binding of AZA-
9 in the RNA-binding cleft of HuR.  Our results show that AZA-9 blocks key ARE-binding residues of 
HuR and disrupt HuR-ARE interactions. 
 
 
6.2.  Introduction 
 
The limited lifetime and subsequent decay of messenger RNA (mRNA) is an important 
mechanism for posttranscriptional regulation of gene expression.  In mammalian cells, mRNA decay is 
dependent on both cis elements located in the RNA and trans acting regulatory factors such as RNA-
binding proteins.  AU-rich elements (ARE) in 5’- or 3’-untranslated region (UTR) of mRNAs are the 
most common cis elements that promote rapid degradation of mRNAs (1,2).  Specific RNA-binding 
proteins can bind to these AREs and either accelerate decay or protect mRNA from degradation (1-4). 
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The RNA-binding protein Hu antigen R (HuR), a ubiquitous member of the ELAV/Hu protein 
family, binds and stabilizes ARE-containing mRNAs that encode oncoproteins, cytokines, growth factors 
and transcription factors (3-7).  HuR is a multi-domain protein containing three RNA-recognition motifs, 
RRM1, RRM2, and RRM3, with each RRM comprising of about 80 amino acids.   High affinity binding 
of HuR to ARE of mRNA is accomplished via its two tandem N-terminal RRM, RRM1 and RRM2 that 
are separated by a 7-residue inter-domain linker (8).  The third RRM of HuR, RRM3, along with the basic 
hinge region that connects RRM2 with RRM3 mediate cooperative assembly of HuR oligomers on RNA 
(9).  Although HuR is predominantly nuclear, the protein rapidly translocates to the cytoplasm in response 
to stimuli mediated by a nucleo-cytoplasmic shuttling sequence located in the hinge region (10).  
 
 HuR is overexpressed in a wide variety of cancer, including colon, ovarian, brain, breast, cervical, 
and pancreas (7,11-13).  HuR promotes tumorigenesis by binding to cancer-associated ARE-containing 
mRNAs, which encode proteins implicated in tumor cell proliferation, cell survival, angiogenesis, 
invasion, and metastasis (7,14-16).  HuR binds to the AREs of the oncogene Musashi1 (Msi1) and anti-
apoptotic proteins, Bcl-2 and XIAP, thereby up-regulating their expression and activating the Wnt/Notch 
signaling pathway and inhibiting apoptosis (14,17,18).  Disrupting HuR-ARE interaction is thus an 
attractive strategy in developing new cancer therapeutics (15,19-21).   
 
 Here, using a fluorescence polarization-based screening (21), we identified azaphilones (a class of 
compounds derived from the fungal natural product asperbenzaldeyde) (22,23) as potent inhibitors of 
HuR-ARE interaction in vitro.  We characterized the HuR binding of the most potent azaphilone 
derivative, azaphilone-9 (AZA-9), by surface plasmon resonance (SPR), nuclear magnetic resonance 
(NMR), and computational modeling.  AZA-9 disrupts HuR-ARE interaction by competitive binding in 
the RNA-binding cleft of HuR. 
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6.3.  Methods 
 
6.3.1.  Protein expression and purification   
 
 The protein expression and purification of full length HuR (326 residues) and HuR RRM1/2 
(residues 18 - 186) have been described (21).  For NMR studies, in addition to 15N-labeling, we also 
performed ILV-labeling, where the Isoleucine C1 and the geminal Leucine C and Valine C methyl 
groups are 13C-labeled by growing E. coli in M9 minimal media supplied with the appropriate 13C alpha 
keto acids.   His6-tagged HuR RRM1/2 labeled with 15N and ILV together was prepared by expression in 
E. coli BL21 (DE3) grown in 1 liter of M9 minimal media supplemented with 1 g of 15N-ammonium 
chloride and 3 g of glucose at 37 °C.  At OD600 ~0.4, the growth medium was supplied with 60 mg of 2-
ketobutyric acid-4-13C (Sigma #571342) to label the 13C1 methyl group of isoleucine and 100 mg of 2-
keto-3-(methyl-13C)-butyric acid-4-13C  (Sigma #571334) to label the two leucine 13C and the two valine 
13C methyl groups (24).  Approximately 1 hour later (at an OD600 of  ~0.8), the culture was induced with 
0.7 mM isopropyl-β-D-thiogalactopyranoside (IPTG), and cell growth was continued overnight in a 15 °C 
shaker incubator to a final OD600 ~2.5.  Cells were harvested by centrifugation (4000 rpm, 10 min), 
resuspended in binding buffer (30 ml; 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 5 mM imidazole), and 
lysed by sonication in the presence of 0.1 mM phenylmethanesulfonylfluoride (PMSF).  Cellular debris 
was removed by centrifugation (13,000 rpm, 10 min), and 600 l of 5% (v/v) polyethyleneimine was 
added to the supernatant to precipitate the nucleic acids.  Following centrifugation (13,000 rpm for 10 
min), the supernatant was purified by nickel affinity chromatography.  The supernatant was loaded to the 
Ni2+ column, washed with binding buffer and he His6-tagged HuR RRM1/2 was eluted with elution buffer 
(500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole).  The HuR RRM1/2 construct used herein 
retained an N-terminal His6-tag.  Purified protein was dialyzed in buffer (100 mM NaCl, 10 mM NaPO4 
pH 6.8) and concentrated using Amicon Ultra 3K centrifugal filter (Millipore).  Protein concentration was 
measured by A280.  
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6.3.2.  ILV assignment   
 
 Mutagenesis was used to assign the ILV resonances by introducing conservative mutations (IL, 
LI, and VI) in HuR RRM1/2.  The QuikChange kit (Stratagene) was used to introduce site-directed 
mutants and mutations were verified by DNA sequencing.  Proteins obtained from cell growth in 200 mL 
of M9 minimal media supplied with the appropriate 13C-alpha keto acid was enough to obtain 2D 1H-13C 
HSQC to assign the ILV peaks of the 12 isoleucine and L39, L61, V66, and L138 residues of HuR 
RRM1/2.  
 
6.3.3.  Chemicals and reagents   
 
 Synthetic RNA oligos were from Dharmacon.  For fluorescence polarization (FP) or AlphaLISA 
(ALPHA) assay, fluorescein-tagged or 3’-biotin modified AREMsi1 oligo derived from the 3’-UTR of 
Musashi RNA-binding protein 1 (Msi1) with the sequence 5’-GCUUUUAUUUAUUUUG-3’ was used.  
For NMR studies, the 11-mer AREc-fos RNA oligo (5’-AUUUUUAUUUU-3’) identical to the c-fos RNA 
sequence used in the crystal structure of HuR-RNA complex (8) was used.  Prior to the addition of RNA 
to the protein, the RNA was heated at 95 C for 5 min followed by immediate cooling on ice for 5 min.  
The azaphilone derivatives used herein were obtained by semisynthetic diversification of 
asperbenzaldehyde, which was purified from a strain of Aspergillus nidulans that was engineered to 
overproduce this compound as described elsewhere (22,23).  Compounds were dissolved in dimethyl 
sulfoxide (DMSO) to form 10 mM stock solutions; for NMR studies, deuterated dimethyl sulfoxide (d6-
DMSO) was used. 
6.3.4.  Biochemical assays   
 
 FP and ALPHA competition assays for screening HuR inhibitors and validation of hits were 
carried out as reported (21).  Briefly, compounds with increasing doses were added to plate wells prior to 
the addition of pre-formed protein-AREMsi1 complex.  This was followed by the addition of streptavidin-
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coated donor beads and nickel chelate (Ni-NTA) acceptor beads in the ALPHA assay.  Measurements 
were taken using a BioTek Synergy H4 hybrid plate reader (Biotek, Winooski, VT) after incubating for 2 
hours at room temperature.  IC50, the drug concentration causing 50% inhibition, was calculated by 
sigmoid fitting of the dose response curve using GraphPad Prism 5.0.  Ki values were calculated 
following method of Nikolovska-Coleska et al. (25).  Percent inhibition was calculated by comparing to 
the DMSO (0% inhibition) and labeled free RNA only (100% inhibition) controls.   
 
Surface plasmon resonance (SPR) datasets were acquired using a BIACORE 3000 (GE 
Healthcare) at 20°C as described (21).  Briefly, HuR was immobilized into a CM5 chip by amine-
coupling chemistry and AZA-9 dissolved in buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 
0.05% p20 (v/v), 5% DMSO (v/v)) was injected into the flow cell at a flow rate of 60 L/min.  The 
mixtures complexes were allowed to associate for 400 sec and dissociate for 160 sec.  SPR sensorgrams 
were generated using Scrubber2 (BioLogic Software, Australia).  
 
6.3.5.  NMR spectroscopy   
 
 Proteins for NMR were dissolved in NMR buffer (100 mM NaCl, 10 mM NaPO4 pH 6.8, 10% 
D2O).  15N NMR data were acquired using Bruker Avance 800 MHz spectrometer with a TCI cryoprobe.  
ILV 13C NMR data were acquired using on a Bruker Avance III 600 MHz spectrometer.  NMR data were 
acquired at 25 C, processed using NMRPipe (26) and analyzed using NMRView (27).  For 15N and ILV 
chemical shift mapping, 80M 15N/ILV-labeled HuR RRM1/2 was titrated with unlabeled AREc-fos RNA 
at increasing molar ratios of 1:0, 1:0.5, 1:1, and 1:1.7.  AZA-9 was titrated at 1:1 and 1:2 molar ratios into 
50M 15N/ ILV-labeled HuR RRM1/2 in NMR buffer with 10% d6-DMSO.  Higher protein 
concentrations or higher molar ratios of AZA-9 resulted in sample precipitation.  The 15N titrations were 
monitored by acquiring 2D 1H-15N TROSY spectra, and the ILV titrations were monitored by acquiring 
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2D 1H-13C HSQC spectra.  The published backbone amide assignments of HuR RRM1/2 (BMRB entry 
26628) (19) and the ILV assignments made herein were used in the NMR analysis.   
 
6.3.6.  Computational modeling   
 
A docked model of how AZA-9 may bind to HuR RRM1/2 was built using the crystal structure of 
HuR RRM1/2 in complex with RNA (PDB 4ED5) (8).  FRED (version 3.0.1) from OpenEye Software 
was used for molecular docking (28).  For each of the biological units present in PDB 4ED5, the RNA 
was removed and a receptor was built using APOPDB2RECEPTOR (OpenEye Scientific Software, Santa 
Fe, NM) with residue Y63 specified as the active site residue.  Conformers of AZA-9 were generated with 
OMEGA (version 2.5.1.4) (29) and docked into each of the prepared receptors using FRED.  Full-atom 




6.4.  Results 
 
6.4.1.  Protein expression and purification of HuR and HuR RRM1/2   
 
 Full length HuR and a shorter HuR construct consisting only of the two tandem RRM1 and 
RRM2 (RRM1/2; residues 18-186) were overexpressed in E. coli BL21 (DE3) and purified under native 
conditions by Ni2+-affinity chromatography.  Typically, ~28 mgs of pure unlabeled or 15N/ILV-labeled 
recombinant HuR RRM1/2 protein was obtained per liter of LB or M9 minimal medium.  The HuR 
RRM1/2 was soluble in 100 mM NaCl, 10 mM sodium phosphate pH 6.8 buffer at a concentration of ~6 
mg/ml (~0.27 mM protein concentration), beyond which it precipitated. 
 
6.4.2.  Identification of AZA-9 as an inhibitor of HuR-RNA interaction   
 
 A high throughput screen based on fluorescence polarization (FP) of HuR and a 16-mer AREMsi1 
RNA oligomer from the 3’-UTR of Musashi1 (Msi1) mRNA identified novel small molecule inhibitors of 
HuR-ARE interactions (21).  This FP-based assay (21) was used here to screen ~2000 compounds from 
NCI (Diversity Set II, natural product set and approved oncology drugs) plus in-house compounds to 
identify inhibitors of HuR-AREMsi1 interaction (screening data not shown).  This screen identified the in-
house fungal natural product azaphilones as potent inhibitors of HuR-AREMsi1 interaction (Figure 6-1).  
Azaphilones are derived from a fungal natural product, asperbenzaldehyde, which exhibit diverse 
biological activities, including cytotoxic, anti-inflammatory, anti-proliferative, and anti-tumorigenic 
(22,31,32).  Eight out of nine azaphilone derivatives (AZA-7 through AZA-15) screened in this assay 
showed significant dose-dependent inhibition of HuR-AREMsi1 interaction (Figure 6-1).  Similar 
inhibitory effects were also observed using other HuR target mRNAs, AREBcl2 and AREXIAP (data not 
shown).  AZA-9 (Figure 6-2A, B) with a Ki value of 0.15 M (n=3) was the most potent compound 
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among the nine azaphilone derivatives and thus was chosen for further characterization by surface 
plasmon resonance (SPR) and NMR methods.  SPR confirmed the direct binding of AZA-9 to HuR 
(Figure 6-2C).  Upon injections of increasing concentrations of AZA-9 on immobilized HuR, SPR 
sensorgrams showed increased optical response in a dose-dependent manner (Figure 6-2C).  
   
 
 
Figure 6-1.  Azaphilones inhibit HuR-RNA interaction.  (A) Dose-response curves of azaphilone 
compounds disrupting HuR-AREMsi1 binding in FP assay using 10 nM HuR protein and 2 nM fluorescein-
labeled Msi1 RNA.  Data are representative of three independent experiments; IC50 and Ki values are 
mean from three independent experiments.  (B) Structures of azaphilone compounds tested in FP assay.  





Figure 6-2.  AZA-9 inhibits HuR-AREMsi RNA interaction and binds directly to HuR.  (A) Structure 
of AZA-9.  (B) Dose-response curve of AZA-9 disrupting HuR-AREMsi1 binding in a fluorescence 
polarization-based assay using 10 nM HuR and 2 nM fluorescein-labeled AREMsi1 (n = 3; number of 
independent experiments).  (C) SPR sensorgrams of AZA-9 injected at increasing concentrations of 0-125 
uM into a flow cell containing immobilized HuR (n=2).  Data courtesy of Dr. Xiaoqing Wu (FP inhibition 
assay) and Dr. Lan Lan (SPR). 
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6.4.3.  Use of HuR RRM1/2 in this study   
 
Full length HuR gave non-ideal NMR spectra that made further NMR characterization 
challenging (19), we therefore used a shorter version of HuR comprising the tandem RRM1/2 domains 
(HuR RRM1/2).  The smaller HuR RRM1/2 construct recapitulated the RNA binding and the inhibitory 
effect of AZA-9 as seen in the full length HuR.  Results of FP assay (21) showed that AZA-9 
significantly inhibited HuR RRM1/2-AREMsi1 binding with a sub-micromolar Ki value (Figure 6-3A).  
Likewise, results of AlphaLISA assay (ALPHA) (21) demonstrated dose-dependent HuR RRM1/2-




Figure 6-3.  Compound AZA-9 displays dose-dependent inhibition with HuR RRM1/2 in FP and 
AlphaLISA assays.  Dose-response curves of compound AZA-9 disrupting HuR RRM1/2-AREMsi1 
binding in (A) FP assay using 25 nM HuR RRM1/2 protein and 2 nM fluorescein-labeled Msi1 RNA; and 
(B) ALPHA assay using 100 nM HuR RRM1/2 protein and 25 nM biotin-labeled Msi1 RNA.  A and B 
are representative of three independent experiments.  IC50 and Ki values are mean from three independent 
experiments.  Data courtesy of Dr. Xiaoqing Wu. 
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6.4.4.  NMR titrations of 15N-labeled HuR RRM1/2 with AREc-fos   
 
 The 2D 1H-15N TROSY spectrum of HuR RRM1/2 (Figure 6-4A) closely resembled the reported 
2D 1H-15N HSQC spectrum (19), thereby allowing use of the reported backbone amide assignments of 
HuR RRM1/2 (19) in our analysis.  Overall, the 2D 1H-15N spectrum of HuR RRM1/2 is well dispersed 
with ~175 sharp, well-resolved peaks as expected for the construct (Figure 6-4A).  To gain insights into 
the interaction of HuR RRM1/2 and RNA in solution, we used the same 11-mer c-fos RNA oligo (AREc-
fos) used in the co-crystallization of HuR RRM1/2 (8) for the NMR characterization of protein-RNA 
interaction.  15N-labeled HuR RRM1/2 was titrated with increasing concentrations of unlabeled AREc-fos 
at 1:0.5, 1:1, and 1:1.7 molar ratios, and the titration was monitored by acquiring 2D 1H-15N TROSY 
spectra. The stepwise addition of AREc-fos induced mainly peak broadening of specific HuR RRM1/2 
resonances (Figure 6-4A) indicating that the interaction occurred in intermediate exchange NMR time 
scale for the backbone amides.  Protein-RNA contacts have been identified in the co-crystal structure of 
HuR RRM1/2-AREc-fos (8).  Some essential HuR residues identified contributing to the specific 
recognition of RNA substrate through side-chain, main-chain and/or stacking interactions include Y26, 
R97, I103, Y109, and R153 (8).  These residues showed significant peak intensity reduction during the 
NMR titration (Figure 6-4B).  To identify the amino acids involved in AREc-fos binding, we calculated the 
peak intensity ratio (I1:1/I1:0) for each non-overlapped peak at an HuR RRM1/2:RNA molar ratio of 1:1 
(Figure 6-4C).  Residues with peak intensity ratio lower than average intensity minus one standard 
deviation were mapped onto the co-crystal structure of the protein-RNA complex (Figure 6-4E).   HuR 
RRM1/2 residues with significant peak intensity reduction cluster together in the -strands, surrounding 
loops and linker region of RRM1/2 and form the RNA-binding surface of RRM1/2 (Figure 6-4E).  The 




 Although the HuR RRM1/2 residues directly in contact or in close proximity with the RNA 
showed reduction in peak intensities as described above, several residues distant from the RNA-binding 
site showed changes in peak positions in the presence of RNA (Figure 6-4A).  Inspection on these peaks 
at lower contour level showed appearance of a new peak at a slightly different frequency with increasing 
concentrations of RNA (Figure 6-4D).  The original peak from the RNA-free form of HuR RRM1/2 
gradually broadens, while the new peak emerging from the RNA-bound form progressively gains 
intensity with increasing amounts of RNA.  HuR RRM1/2 residues displaying such shifts were mapped 
onto the structure of RNA-bound HuR (Figure 6-4E, residues colored yellow).  Because these residues 
are situated ~9-13 Å apart from the RNA-binding site, such perturbations can be most directly interpreted 
a result of conformational change upon RNA binding.  The appearance of two peaks corresponding to 
HuR RRM1/2 residues distant from the RNA-binding site in the presence of RNA is suggestive of slow 
conformational switching of HuR upon RNA binding.  The allosteric effects observed in solution are in 
agreement with crystal structures and SAXS analysis of RNA-free versus bound forms of HuR that 
demonstrate conformational changes play a major role in formation of a stable compact HuR RRM1/2-
RNA complex (8,33). 
 
6.4.5.  NMR assignment of ILV-labeled HuR RRM1/2   
 
ILV labeling offer additional probes in NMR studies because of their high sensitivity.  Similar to 
the amide signals shown above, perturbations of 13C methyl peaks can be used to report on protein ligand 
interactions, conformational changes, structure and dynamics (24,34,35).  Further, side-chain interactions 
are crucial for the RNA recognition of HuR and methyl-containing residues such as isoleucine, leucine, 
and valine (ILV) occur near the RNA cleft.  We therefore used ILV-labeled HuR RRM1/2 here to probe 
the side-chain protein-RNA interaction.  His6-tagged HuR RRM1/2 contains 12 isoleucine, 15 leucine and 
13 valine residues (the His-tag contributes 1 valine and 2 leucines).  The 2D 1H-13C methyl HSQC 
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spectrum of HuR RRM1/2 (Figure 6-5A) showed 12 Ile peaks (corresponding to each of the 1 methyl 
group of 12 isoleucine) within the spectral window ~8-16 13C ppm and 28 pairs of Leu and Val peaks 
(corresponding to the two 1 and 2 methyl groups of 15 leucines; and the two 1 and  methyl groups 
of 13 valines) within 19-28 13C ppm range.  To assign the 16 ILV residues used herein, fifteen point 
mutations were introduced in HuR RRM1/2 (with isoleucine mutated to leucine; and leucine or valine 
mutated into isoleucine), and the resultant protein expressed and purified under native conditions.  
Comparable to the wild type construct, the mutant proteins were soluble at ~6 mg/ml in 100 mM NaCl, 10 
mM sodium phosphate pH 6.8 buffer.  To illustrate the assignment method to assign I23 for example, 
comparison of the 2D 1H-13C HSQC spectrum of the I23L point mutant that was selectively 13C-labeled at 
the isoleucine 1 methyl with the spectrum of the wild type protein (Figure 6-6A), enabled the 
unambiguous assignment of the 13C 1 methyl resonance of I23.  All the 12 isoleucine residues were 
assigned in addition to 3 leucines (L39, L61, and L138) and a valine residue, V66 (Figure 6-5A).  These 
16 ILV probes are strategically located and provide overall coverage of the HuR RRM1/2 structure. 
 
6.4.6.  Titrations of ILV-labeled HuR RRM1/2 with AREc-fos   
 
To monitor the effect of RNA binding on ILV methyl resonances of HuR RRM1/2, 2D 1H-13C 
HSQC spectra were acquired on various titration samples.  Of the assigned side chain methyl resonances, 
peaks corresponding to I23, I52, and L61 of RRM1, I103 of inter-domain linker region, and I133, L138, 
and I152 of RRM2 disappeared from their free position and reappeared at a different frequency in the 
spectrum as new peaks for the protein-RNA complex (Figure 6-5A).  This indicates that the side-chains 
of these residues either directly mediates tight RNA-binding or are present in close proximity of the RNA 
and thus, experience strong perturbation in their local chemical environment upon RNA-binding.   The 
affected ILV residues (I23, I52, L61, I103, I133, L138, and I152) delineate the RNA-binding cavity of 




Figure 6-4.  Amide titrations of HuR RRM1/2 with RNA.  (A) Overlay of four 2D 1H-15N TROSY 
spectra of 15N HuR RRM1/2 titrated with increasing molar ratios of AREc-fos RNA.  Representative 
residues showing peak broadening (dashed box) and residues displaying changes in peak positions (solid 
box) are shown.  (B) Representative residues displaying peak broadening upon RNA binding are shown at 
similar contour levels.  (C) Plot of relative peak intensity for all non-overlapping HuR RRM1/2 
resonances in the ligand bound versus free state (I1:1 /I1:0).  Gray and red lines correspond to the mean and 
one standard deviation from the mean (1), respectively.  (D) Representative residues that displayed 
changes in peak positions are shown at similar contour level at individual titration points.  While the 
original peak (RNA-free form) gradually decreases in intensity, a new peak (shown by arrow) appears and 
progressively gains intensity with increasing concentrations of RNA.  (E) Results of NMR titrations 
mapped onto the co-crystal structure of HuR-AREc-fos complex (PDB 4ED5) and colored as follows:  
RRM1/2 residues with peak intensity ratio (I1:1 /I1:0) lower than 1 (red), residues with new peaks shown 






Figure 6-5.  ILV titrations of HuR RRM1/2 with RNA.  (A) Overlay of five 2D 1H-13C HSQC spectra 
of ILV-labeled HuR RRM1/2 titrated with increasing concentrations of unlabeled AREc-fos.  Assigned ILV 
peaks, the new peaks appearing upon complex formation (*), and Some representative ILV residues away 
from the RNA-binding site that showed chemical shift perturbations (boxed) are indicated.  (B) The 
boxed peaks in A are shown at similar contour levels at individual titration points.  The new peak 
emerging with increasing concentrations of RNA is shown by an arrow.  (C) Results of NMR titration 
mapped onto the crystal structure of HuR-AREc-fos complex (PDB 4ED5).  Protein and RNA are 
represented as in Figure 6-4.  Assigned ILV residues (red) are shown as sticks (Ile) and with spheres (Leu 
and Val) and colored as follows:  RRM1/2 residues showing new complex peaks (red) and residues with 




Figure 6-6.  Single amino acid site-directed mutagenesis approach used in assigning selective methyl 
peaks of HuR RRM1/2.  2D 1H-13C methyl HSQC spectra for HuR RRM1/2 mutants (red) overlaid with 
the wild type reference spectra (black).  (A-K) A single missing 13C1 methyl peak for Ile; and (L) Two 
13C1 and 13C2 methyl peaks for Leu corresponding to the mutated residue are labeled. 
 
Analogous to the allosteric effects observed in the backbone amide titrations (Figure 6-4D), 
several residues, such as L39, I43, V66 of RRM1, and I110, I132, I164, I179 of RRM2, with the side 
chain methyl group that are positioned ~12-18 Å from the RNA binding site also showed changes in their 
chemical shift positions (Figure 6-5B).   The original free peak disappeared and a new peak representing 
the RNA-bound form of HuR appeared at a slightly different position (Figure 6-5B).  After 1:1 complex 
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is reached, it was observed that the addition of RNA merely adds to the intensity of the peak of the bound 
form.  Residues with such perturbations are highlighted as yellow sticks in Figure 6-5C.  The appearance 
of new peaks for such distant residues in the RNA-bound form confirms conformational changes upon 
RNA-binding.  The results of side-chain ILV methyl titrations complement backbone amide titrations and 
together, they support that the -sheet region of HuR RRM1/2 is the RNA binding surface and RNA 
binding is accompanied by conformational changes in HuR.   
 
6.4.7.  NMR titrations of HuR RRM1/2 with AZA-9   
 
The interaction of AZA-9 with HuR RRM1/2 was characterized by NMR methods.  Titrations of 
15N/ILV-labeled HuR RRM1/2 with AZA-9 resulted in concentration dependent reduction in the 15N and 
ILV peak intensities of HuR RRM1/2 (Figure 6-7), indicating complex formation on an intermediate 
exchange time scale.  In addition to the decrease in peak intensities, the side chain methyl groups of some 
HuR RRM1/2 residues, such as I103, L138 (Figure 6-7D), also showed chemical shift deviations upon 
binding of AZA-9.  Further, key RNA-binding residues, Y26, R97, I103, Y109, and R153 (Figure 6-4A), 
exhibited significant peak broadening with increasing doses of AZA-9 in the 15N-titrations (Figure 6-7B).  
Specifically, residue R97 in the inter-domain linker region (whose intensity reduced by ~50% at 
equimolar concentration of AZA-9, Figure 6-7C) has been previously reported as important for RNA 
binding, RNA recognition and high affinity HuR-RNA complex formation (8).  Comparable to the results 
of the amide titrations, results of the ILV titrations of other RNA-binding residues, such as I52, L61, I103, 
and L138, identified earlier (Figure 6-5A) also displayed significant reduction in peak intensities upon 
addition of AZA-9 (Figure 6-7D).  A plot of the peak intensity ratio (I1:1/I1:0) in the bound and free form 
at 1:1 molar ratio (Figure 6-7C, 6-7E) revealed that the NMR resonances of the major RNA-binding 
residues of HuR, including K55, G62, R97, I103, L138, and R153, were significantly perturbed by AZA-
9.  Residues that were significantly perturbed during titrations were mapped on the structure of RNA-
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bound HuR (Figure 6-7F).  Complex formation with AZA-9 primarily affected a cluster of RNA-binding 
residues located near the inter-domain linker region of HuR (Figure 6-7F).  NMR results indicate that 
AZA-9 interacts at the same binding pocket that HuR RRM1/2 uses to bind its target RNA. 
 
6.4.8.  In silico docking of AZA-9 in the RNA cleft of HuR RRM1/2   
 
Molecular docking studies were performed to gain further insight into the binding mode of 
compound AZA-9 to HuR.  Figure 6-8A represents the top-scoring computational model of compound 
AZA-9 bound HuR RRM1/2 generated using FRED (28) following full-atom minimization with 
ROSETTA (30).  Consistent with the NMR-derived binding site of AZA-9 (Figure 6-7E), molecular 
docking confirmed a feasible binding mode for compound AZA-9 in the RNA binding cleft of HuR near 
the inter-domain linker region (Figure 6-8A).  Several hydrophobic and positively charged HuR residues, 
such as Y26, K55, R97, and R153 line the pocket for AZA-9 and potentially stabilize the protein-ligand 
complex through electrostatic, hydrogen bond, hydrophobic, and pi-stacking interactions (Figure 6-8A).  
Together, results of NMR titrations and molecular docking indicate that compound AZA-9 disrupts HuR-
RNA interaction by competitively binding in the RNA cleft of HuR (Figure 6-8). 
 
 
6.5.  Discussion 
 
HuR-ARE interaction (1,4-6) contributes to carcinogenesis by stabilizing the mRNAs of 
oncogenes (7,11,14,17,18), thus, finding inhibitors of HuR-ARE interaction could contribute in the 
development of new cancer therapy (19,21).  So far, there has been limited success in the discovery of 
HuR inhibitors that competitively bind to HuR that directly disrupt the HuR-ARE interactions (19-21).  
Currently, the most potent HuR inhibitor known, MS-444, is a bacterial natural product isolated from 
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Actinomyces sp. microbial broths, and MS-444 inhibits HuR-RNA interaction by interfering with HuR 
homodimerization (20).  Here, we identified a new class of compounds, azaphilones (Figure 6-1) (31,32) 
and in particular, AZA-9 (Figure 6-2), as novel inhibitors of HuR-ARE interaction. 
 
Azaphilones are derived from the fungal secondary metabolite asperbenzaldehyde (22,23).  
Fungi-derived natural products are excellent sources of pharmaceuticals and many fungal secondary 
metabolites show anti-cancer properties that inhibit cell proliferation, angiogenesis, and tumorigenesis 
(31,36,37).  The two rings of azaphilones form the isochromene scaffold, and this scaffold is present in 
the previously identified methyl-benzoisochromene scaffold of the chrysanthones secondary fungal 
metabolites isolated from another fungi, Ascochyta chrysanthemi (37).  Chrysanthones were reported to 
have anti-proliferative, anti-tumorigenic and anti-angiogenic properties, however, their specific molecular 
target was not determined (37).  The presence of the isochromene scaffold plus the observed anti-cancer 
properties of chrysanthones could be associated to HuR inhibition. 
 
The tandem RRM1/2 of HuR is the minimal domain needed for binding AREs.  Our results of the 
backbone amide titrations showed significant peak broadening for the ARE-binding residues similar to 
what was reported by Wang et al. (19) (Figure 6-4), however, we also observed additional new slow 
exchange peaks in the ILV titrations (Figure 6-5).  This differing NMR exchange behavior could be due 
to the direct interactions of the protein side chains with the RNA substrate and their dominant role in the 
formation of tight HuR RRM1/2-ARE complex (8).  Additionally, we observed allosteric effects in HuR 
RRM1/2 occurring upon RNA binding (Figure 6-4D and Figure 6-5B).  Conformational changes in HuR 
RRM1/2 on binding the RNA substrate have been previously reported (8,33).  These conformational 
changes contribute in the formation of a stable, high-affinity HuR RRM1/2-RNA complex.  Consistent 
with the crystal structures and SAXS analysis (8,33), our NMR results identified the specific residues 
(such as M31, T70, R85, Q141, A163, and G169) that are involved in the slow conformational switching 




Figure 6-7.  NMR titration of HuR RRM1/2 with AZA-9.  (A) Overlay of three 2D 1H-15N TROSY 
spectra of 15N HuR RRM1/2 titrated with increasing molar ratios of AZA-9.  The peaks of some critical 
RNA-binding residues that undergo significant line broadening upon addition of AZA-9 are shown 
(expanded dashed box).  (B) Representative residues showing peak broadening upon titration of AZA-9 
are shown at similar contour levels at individual titration points.  (C) Relative peak intensity plot for non-
overlapping amide resonances of HuR RRM1/2 in the ligand bound versus free state (I1:1 /I1:0).  (D) 
Overlay of three 2D 1H-13C HSQC spectra of ILV-labeled HuR RRM1/2 titrated with increasing molar 
ratios of AZA-9.  Analogous to 15N-titrations, ILV methyl groups of RNA-binding residues showed peak 
broadening with a few residues such as I103 and L138 also displaying chemical shift deviations (dashed 
box).  (E) Relative peak intensity plot for assigned ILV methyl HuR RRM1/2 resonances in the ligand 
bound versus free state (I1:1 /I1:0). (F) Results of titrations mapped onto the co-crystal structure of HuR-
AREc-fos complex (PDB 4ED5).  Protein and RNA are shown as in Figure 6-4 and 6-5, and depicted as 
follows: RRM1/2 residues with peak intensity ratio (I1:1 /I1:0) lower than 1 (red) and the proposed AZA-9 
binding site (arrow). Most of the AZA-9 affected residues are key RNA-binding residues.  (C,E) Gray 






Figure 6-8.  Molecular docking identified a possible binding pocket for AZA-9 in the RNA-cleft of 
HuR.  (A) Computational model of AZA-9 bound to HuR RRM1/2, with protein shown in surface 
representation and AZA-9 in sticks.  HuR RRM1/2 residues affected in AZA-9 NMR titrations are 
colored red.  An expanded view of the drug-binding pocket is shown in the right.  Residues involved in 
AZA-9 binding are displayed as sticks, with hydrogen bonds shown as dashed lines.  (B) Surface 
representation of HuR RRM1/2 bound to RNA (blue sticks) for comparison with the AZA-9 model.  
Residues affected upon RNA titrations are highlighted in red.  An expanded view of the RNA-pocket is 
shown in the right.  Residues (Y26, K55, L61, R97, R153) perturbed by AZA-9 in the NMR titrations are 
critical RNA-binding residues.  Computational modeling by Dr. David Johnson. 
 
The crystal structures of the free and RNA-bound HuR RRM1/2 (8) suggest major structural 
rearrangements in the relative orientation of RRM1 with respect to RRM2 upon RNA binding (Figure 6-
9).  For example, RRM2 have to swing about 41 Å to reposition itself vis-à-vis RMM1 upon RNA 
binding (Figure 6-9).  This major conformational change in HuR RRM1/2 upon RNA binding is not 
reflected in the results of our NMR titrations as well as the results of the amide titrations of Wang et al. 
(19).  For such major conformational rearrangements of the two RRM domains, one would expect major 
changes in the peak positions in the 15N TROSY spectra of the free and RNA-bound HuR RRM1/2 
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(Figure 6-4).  Instead, we observed essentially similar peak positions in the 15N TROSY of free and 
RNA-bound HuR RRM1/2 (Figure 6-4), with the peak intensities of the RNA-bound form progressively 
weakening upon addition of more RNA.  In the ILV-titrations (Figure 6-5), there were indeed new slow-
exchange peaks for RRM2 isoleucine residues (I103, I133, I152) but the rest of the isoleucines in RRM2 
(I110, I164, and I179) were essentially in similar (fast exchange) peak positions as the free form 
suggesting the changes in the peak positions and intensities observed by NMR are due to RNA-binding 
rather than the major conformational rearrangements of the two domains upon RNA-binding.  Our NMR 
results suggest that RRM1 and RRM2 are somewhat ‘pre-formed’ for RNA-binding with the two domains 
already close together and poised to accept the RNA.  Upon RNA-binding, the side chains and loops of 
HuR RRM1/2 ‘wiggle’ to accommodate and interact with the RNA.  SAXS results suggest two 
populations of free HuR RRM1/2 where one population has an extended structure (with a size of 74 Å) 
and another population that has a more compact structure (with a size of 56 Å) (33).  Upon RNA binding, 
the HuR RRM1/2 becomes even more compact (with a size of 51 Å).  This suggest that SAXS is able to 
trap two populations of free HuR RRM1/2 whereas our NMR results suggest an average conformation 
that is somewhat poised for RNA binding. 
 
Our efforts to co-crystallize AZA-9 with HuR RRM1/2 have been so far unsuccessful, thus, we 
used NMR methods to characterize how AZA-9 interacts with HuR RRM1/2.   Results of NMR titrations 
showed that AZA-9 essentially perturbs the same HuR RRM1/2 residues involved in binding RNA 
(Figure 6-7).   NMR titrations with AZA-9 affected specific RNA-binding residues of HuR RRM1/2 
(Figure 6-7).   The previously identified key ARE-binding residues, including Y26, L61, R97, I103, 
Y109, and R153 that make side chain, main chain and/or stacking interactions with the ARE substrate (8), 
showed significant perturbations upon the addition of AZA-9 (Figure 6-7A, 6-7B).  Particularly, R97 in 
the inter-domain linker region showing strongest peak intensity reduction has been identified through 
mutagenesis as a critical residue required for high affinity ARE binding (8).  Together, results of both 
backbone amide and ILV titrations indicate that AZA-9 predominantly affects a surface near the inter-
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domain linker region in the RNA cleft of HuR (Figure 6-7F).  Although few ARE-binding residues 
(Y109, L138) in the lower region of the RNA-cleft also showed perturbations, this could be due to 
conformational changes induced by AZA-9 upon binding in the upper portion of the cleft or a second 




Figure 6-9.  Comparison of the crystal structure of (A) RNA-bound, PDB ID: 4ED5; and (B) RNA-
free HuR RRM1/2, PDB ID: 4EGL.  (C) Superposition of RRM1 from the RNA-bound and RNA-free 
forms of HuR RRM1/2.  RRM1 is colored green, RRM2 is orange, and RNA is blue. 
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In agreement with the NMR-derived binding site of AZA-9, results of molecular docking 
positioned AZA-9 in the ARE-binding cleft near the inter-domain linker region of HuR RRM1/2 (Figure 
6-8A). Computational modeling suggested that AZA-9 is well situated in the binding pocket surrounded 
by several positively charged and hydrophobic residues to enable hydrophobic, hydrogen bond, and/or 
electrostatic interactions.  In the computational model, the long hydrophobic tail of AZA-9 lies adjacent 
to the methyl side chain of I23, and runs roughly parallel to the aliphatic chain of R97 to promote 
hydrophobic interactions; the oxygen atom of the pyran ring in AZA-9 positioned such that it can form a 
hydrogen bond with the guanidinium group of R97; and the ester carbonyl of AZA-9 lies very close to the 
guanidinium side chain of R153 to form a salt bridge.  The ability of AZA-9 to interact with R97 is 
particularly significant as R97 is a key residue for stable HuR-ARE complex formation as identified by 
crystallography.  Overall, our results show that AZA-9 competes with target mRNAs for binding in the 
RNA cleft of HuR RRM1/2 
 
To summarize, we discovered azaphilones, which are derived from fungal natural products, as 
novel disruptors of HuR-RNA interaction.  Results of SPR, NMR and molecular docking confirmed that 
the most potent azaphilone derivative, AZA-9, inhibited HuR-mRNA interaction by competing directly 
for the RNA-binding site in HuR RRM1/2. 
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